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General introduction 
General introduction Pathophysiology of Chronic Heart Failure Chronic heart failure (CHF) is defined as the inability of the heart to maintain organ perfusion, due to impaired cardiac contractility and dilation, ie. systolic heart failure. This fall in cardiac output is accompanied by complaints like, dyspnea and fatigue, fluid retention and impared exercise intolerance.1• 2 The severity of heart failure symptoms usually progresses over time and is classified according to the classification of the New York Heart Association (NYHA). The most common cause of CHF in western countries is ischemic heart disease, comprising 50-75% of patients with heart failure. Other causes are volume load due to aortic or mitral valve regurgitation, hypertension, myocarditis or the prolonged presence of tachycardia.3 After the initial damage of the myocardium, several adaptational mechanisms are able to maintain cardiac function for a limited period of time. Initially there is an increase in sympathetic activity, which helps to restore cardiac output by increasing both contractility and heart rate. Due to renal hypoperfusion and the sympathetic stimulation the renin-angiotensin-aldosterone­system (RAAS) is activated. Resulting in vasoconstriction, exacerbaration of the ventricular remodelling through stimulation of pro-hypertrophic and pro-apoptotic signaling pathways in the cardiac myocytes and an expansion of the blood volume by renal salt and water retention. To counterbalance these effects natriuretic peptides are secreted by the cardiomyocyt (brain natriuretic peptide and atrial natriuretic peptide), resulting in vasodilatation, natriuresis and attenuation of hypertrophic signaling pathways in cardiac myocytes. Eventually, the left ventricle (LV) starts to dilate in order to maintain stroke volume (referred to as LV remodeling). However, the LV dilatation and the increased load of the left ventricle may result in a consequent stretch of the mitral annalus inducing and/ or worsening mitral valve regurgitation. This process can be considered as a vicious circle leading to continuing LV dilation which will eventually lead to progressive heart failure symptoms and finally end stage heart failure.2• 3 Prevalence and prognosis of chronic heart failure The prevalence of CHF has been steadily increasing in the population over time. According to epidemiological studies, an estimated 5 million people in the United States have heart failure, with 660.000 new diagnosis each year.4 These numbers are in line with recent European data that report an incidence of 14.4/1000 among persons aged over 55 years.5 Prognosis of CHF is poor, even with the advances in pharmacologic therapies, being ACE inhibitors, beta blockers and spironolactone it is still associated with a high morbidity and mortality rate.6•10 After the first admission for heart failure the I-year survival is 63% and the 5-year survival is only 30%.5• 11 Mortality is related to the severity of heart failure symptoms, the severity of LV dysfunction and the extent ofLV remodeling.6• 7• 12• 13 The predominant modes of death in heart failure patients are death from progressive heart failure or sudden cardiac death due to ventricular arrhythmias or bradycardia. 14• 15 
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General introduction In addition, patients with heart failure suffer from a considerable morbidity. The quality of life of heart failure patients is usually poor, caused by a severely reduced exercise capacity resulting in severe limitations of daily life activities. The rate of hospitalizations for decompensated heart failure has increased by 159% over the last decade which makes heart failure a costly disorder.4• 5, 16 During the 90's cardiac resynchronization therapy (CRT) was introduced as a novel treatment of heart failure patients.17-19 CRT has been developed as a pacemaker technology that aims at resynchronizing the cardiac contraction in patients with asynchronous contraction in order to improve cardiac pumping efficiency. Large CRT trials have shown substantial improvements in patient morbidity and mortality and is therefore considered a major revolution in the treatment of patients with drug refractory heart failure. Rationale for cardiac resynchronization Approximately 25-50% of CH F patients have an intraventricular conduction delay. In most cases this is expressed as a left bundle branch block (LBBB). An intraventricular conduction disturbance is independently associated with functional capacity and cardiac mortality.20• 21 In LBBB, ventricular activation is initiated through the right bundle followed by slow transmyocardial conduction through the septum and further towards the inferior and postero­lateral wall. This abnormal activation sequence leads to delayed contraction of the last activated ventricular segments in the left ventricle and loss of coordination of contraction and relaxation. 22• 
23 As a result, the rise ofLV pressure is slower, effective ejection time shortened and stroke volume decreased.23-25 Furthermore, the decreased left ventricular ejection fraction is worsened by the frequent concomitant mitral valve regurgitation. The underlying pathophysiology for mitral valve regurgitation is diverse, the left ventricular dilation causes incomplete leaflet coaptation, and the dyssynchrony results in papillary muscle dysfunction. 23 The aim of CRT is to restore synchronous left ventricular contraction by pre-exciting the areas of delayed activation. To pre-excite the left ventricle, a pacing electrode is introduced into a suitable vein via the coronary sinus. (Figure I) The hemodynamic benefit of CRT can be further enhanced by optimizing the AV pacing interval and if needed the VV interval.26• 27 Optimal AV delay ensures optimal diastolic filling time and abolishes presystolic mitral valve regurgitation.26· 28 Alteration of the VV delay enables the possibility to pre-excitate the area of delayed activation, and therefore might be able to compensate for a suboptimal left ventricular lead position. 29• 30 11 
General introduction 
Right ventricular lead 
Figure 1 Lead positioning during cardiac resynchronization therapy Clinical results Left ventricular lead Cardiac resynchronization therapy has become a cornerstone in the treatment of chronic drug-refractory heart failure patients with intra- or interventricular conduction disturbances.3 Several studies have demonstrated the immediate benefit of CRT on hemodynamics and systolic performance of the left ventricle. Thereafter, several (randomized) studies demonstrated the long-term beneficial effects of CRT. These studies showed an improvement in clinical (symptoms, exercise capacity, quality of life, hospitalization for heart failure, and mortality) and echocardiographic endpoints (improvement in systolic function, reduction of left ventricular size, and decrease of mitral valve regurgitation).31-36 (Table 1) The Comparison of Medical Therapy, Pacing and Defibrillation, in Heart Failure (COMPANION) and the Cardiac Resynchronization-Heart Failure (CARE-HF) trials are the only prospective multi-center randomized controlled clinical trials to demonstrate that CRT-D and CRT alone, respectively, reduced all cause mortality. Furthermore they confirmed previous findings demonstrating that CRT results in improvement of clinical symptoms, exercise capacity and morbidity.35• 36 The COMPANION-trial is the largest prospective multi-center randomized controlled clinical trial to date and was designed to evaluate the effects of CRT on the composite endpoint of all-cause mortality and all-cause hospitalization. A total of 1,520 patients were randomized to optimal medical therapy, CRT pacemaker (CRT-P) or CRT defibrillator (CRT-D). 
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General introduction The composite endpoint was improved by approximately 19% in the CRT-P group (p=0.01) and 20% in CRT-D group p=0.01). In addition, the risk of death of any cause or hospitalization for heart failure was reduced by 34% in the CRT-P group (p<0.002) and by 40% in the CRT-D group (p<0.001). All-cause mortality was significantly reduced in CRT-D patients with 36% (p=0.003). There was a trend towards an improvement in all-cause mortality in CRT-P patients (p=O. 06). 35 In contrast, the CARE-HF trial was the first CRT-trial to demonstrate that CRT-P improved all­cause mortality. A total of 813 patients were enrolled. All cause mortality was reduced by 36% with CRT-P compared to optimal medical therapy (p<0.002).36 Currently CRT is considered a Class I (level of evidence A) indication for patients with drug refractory heart failure, signs of electromechanical delay and sinus rhythm.3 Cardiac resynchronization therapy and Atrial Fibrillation Atrial fibrillation (AF) is the most common arrhythmia in heart failure.37• 38 The prevalence of AF is related to the functional heart failure NYHA class, varying from 5% for NYHA functional class I, 10-25% for classes II and III, and as high as 50% for class IV.38• 39 However, cardiac resynchronization therapy in CHF patients with AF is still an area of controversy. The fast majority of randomized CRT-trials only included patients in sinus rhythm. Even so, the impact of CRT on (new-onset) AF remains controversial. Hypothetically, improvement of left ventricular function may reduce the occurrence of AF. The issue of non-response to CRT In spite of the impressive results of CRT a considerable number of patients fail to respond to CRT despite application of the established selection criteria (NYHA class III-IV for heart failure despite optimal pharmacological therapy, left ventricular ejection fraction (LVEF) � 35 %, left ventricular end diastolic diameter (LVEDD) � 55 mm and a QRS � 120 ms).3 The percentage of non-responders varies between 20 and 40% depending on which criterion is used to determine response. In the Multicenter lnSync Randomized Clinical Evaluation (MIRACLE) trial, at 6 months follow-up 32% of the patients did not improve or even worsened in NYHA class. The same amounts of clinical non-responders were found in the CARE-HF trial and COMPANION trial. ( table 1) Since, NYHA response is a subjective value which is prone to be influenced by a placebo effect, currently reverse LV remodeling (defined as a decrease of 10% or more in LVESV) is used to determine response. Therefore, this parameter is associated with a better survival.40· 41 Using this parameter for response, response percentage drops to about 60%. 13 
General introduction Predictors for response Since the introduction of CRT there have been several theories with regard to predictors for response. Initially response to CRT was considered to result in part from resynchronization of interventricular dyssynchrony (dyssynchrony between the left and right ventricle).42 Thereafter, it was suggested that intraventricular dyssynchrony (defined as a septal to lateral delay> 60 ms) was predictive for response to CRT.43· 44 However, in a multi-center randomized trial Predictors of response to CRT (PROSPECT), none of the echocardiographic dyssynchrony parameters were able to predict left ventricular end-systolic volume response.45 Also, the underlying heart disease (ischemic or non ischemic) influences response. Positioning of the left ventricular lead in or around scar tissue is associated with non-response.46• 47 In CRT, both ventricular stimulation site and atrioventricular (AV) delay modulate stroke volume. AV interval is crucial in ensuring optimal time for diastolic filling and abolishing presystolic mitral valve regurgitation.48 Several studies have proven the efficacy of AV delay optimization.26• 
49· 50 The optimization of LV filling by measuring diastolic filling time (EA duration) is based on the assumption that the optimal AV delay allows the completion of diastolic filling before ventricular contraction, the A wave not being attenuated by the mitral valve closure.49 Thus, taking into account the amount of non-responders to CRT further research needs to be performed to determine how to improve response to CRT. 
Aims of this thesis The prevalence of AF is high in patients treated with CRT. However, patients with AF are not well represented in the landmark trials that established the clinical benefit of CRT. This indicates the need for further refinement how to handle AF in patients treated with CRT. The aim of the current thesis was to improve and refine the current CRT selection criteria in AF and sinus rhythm patients through evaluation of the mechanisms underlying (non-)response to CRT. In part I the clinical and echocardiographic response rates to CRT were compared between atrial fibrillation patients and sinus rhythm patients. The influence of AF on short and long-term response was studied in chapter 2 and 3. Predictors for response to CRT in atrial fibrillation patients were investigated in chapter 1. Long term prognosis and outcome between atrial fibrillation patients treated with CRT and sinus rhythm patients was studied in chapter 2. In chapter 3 we studied whether CRT prevents new-onset AF and, furthermore, how new-onset AF influences response and prognosis to CRT. In part II predictors for response to CRT were studied. Exercise related factors that influence response to CRT were studied in chapter 4. In chapter 5 we examined the influence of interlead distance measured by thoracic X-ray on response to CRT. Furthermore, the influence of the septal to lateral delay and interventricular mechanical delay were examined. With the improvements in device possibilities the treatment of the CHF patient can be improved. This is described in a case report ( chapter 6). 
14 
General introduction Finally, in the discussion and future directions section of this thesis the results and implications of this thesis are discussed in the context of other studies. Future perspectives of the optimal use of different non-invasive imaging modalities in patients undergoing CRT implantation, both before implantation as well as during follow-up (evaluation of therapy success and optimization of pacemaker settings), are discussed. 15 
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Cardiac Resynchronization Therapy in Patients with Heart Failure and Atrial Fibrillation: Importance of New Onset Atrial Fibrillation and Total Atrial Conduction Time 
Chapter 1 STRUCTURED ABSTRACT Aims. CRT is an established therapy for patients with heart failure and sinus rhythm (SR) but its value in atrial fibrillation (AF) remains unclear. Furthermore, response to CRT may be difficult to predict in these patients. The aim of our study was to investigate if predictors for CRT success differ between patients with AF and SR, and to study the influence of present or developing AF on response to CRT. Methods. We examined consecutive patients in whom CRT was implanted disregarding the atrial rhythm. AF was defined as either current or earlier AF, response to CRT as a decrease in left ventricular end systolic volume of� I Oo/o after 6 months. Total atrial conduction time (TACT), a measure to predict risk of developing AF, was determined by echocardiography. Results. We included 114 patients of whom 56 (49%) were known with AF (23 current AF, 33 earlier AF). The other 58 patients had no history of AF. After 6 months, response in current and earlier AF and in SR patients was comparable (56%, 58% and 55%, respectively). In AF patients, multivariate analysis revealed a shorter TACT at baseline (OR 16.7[1.5- 185.3] , p=0.02) and an interventricular mechanical delay >40ms (OR 10.4 [ 1.0-110.9], p=0.05) as predictors for response. Non-responders more frequently suffered from new onset AF (p=0.02). In AF and SR patients % biventricular pacing was related to CRT-response (p=0.02). Conclusion. Failure to CRT is associated with new onset AF. Total atrial activation time may be a parameter to predict response in AF patients. 24 
Atrial Fibrillation and CRT Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder and often coexists with chronic heart failure. 1 •2 In these patients, AF may increase cardiovascular morbidity and mortality.3•6 Randomized clinical trials have demonstrated the beneficial effects of cardiac resynchronization therapy (CRT) in patients with pharmacological refractory heart failure with prolonged QRS, low ejection fraction and sinus rhythm (SR).7•1 1  Whether CRT is also effective in patients with AF is still to be elucidated. Only a few studies have assessed this issue.1 2- 15 From these limited data it is suggested that CRT is also effective in patients with AF. Hereby it should be noted that in most studies adequate rate control was performed by atrioventricular (AV) node ablation.1 2-14 Identification of success of CRT in general still is a subject of interest. 16  It is unknown if the same predictors of response are valid in patients with SR and AF. Furthermore, it is not dear which patients need AV-node ablation and which could also be treated with rate control medication alone. 1 7-l B  Furthermore, AF may be underestimated because of insufficient documentation. Device therapy can be used to determine actual AF burden in patients with pacemakers or Internal Cardioverter Defibrillators (ICD). New onset AF may influence response to CRT. Yet, only a few studies reported on the prevalence of new onset AF during follow-up and its influence on outcome. 15• 1 9•20 The aim of the present study is to investigate the influence of present or developing AF on response to CRT and to study if predictors for success of CRT differ between patients with AF and SR. 
25 
Chapter 1 METHODS Patient population. Between January 2004 and January 2007, 114 consecutive patients with congestive heart failure who met eligibility criteria for CRT were included. The eligibility criteria for CRT were according to the guidelines: New York Heart Association (NYHA) functional class III or IV despite optimal pharmacological treatment, left ventricular ejection fraction :535%, a LVEDD �55mm, wide QRS complex �130ms.21  In some patients QRS duration differed at acceptance for CRT and actual inclusion. AF was defined as a history of documented AF being either present at baseline (current AF) or in the past (earlier AF). AF during follow-up was defined as any AF documented on an ECG, Holter monitoring (>30 seconds) or detected by the device (duration >30 seconds). AF burden was determined by the device and defined as the time the patient was in AF divided by the total time. Successful response to CRT was defined as a decrease in left ventricular end systolic volume (LVESV) of 10% or more measured by cardiac ultrasound after 6 months of follow-up.22 Baseline assessment included patient history, physical examination, 12 lead electrocardiogram (ECG), transthoracic echocardiography, exercise testing, radionuclide scanning and coronary angiography. Clinical history, AF history and characteristics were carefully retrieved using patient medical records. Dyssynchrony was determined by tissue Doppler imaging, using Echopac 6. 1, General Electric Vingmed". 16 We evaluated aortic pre-ejection time, interventricular mechanical delay (IVMD) and septa! to lateral delay. An IVMD >40ms was considered indicative of IVMD. 16 lntraventricular LV dyssynchrony was measured by calculating the septa! to lateral delay in peak velocities. 16 A mechanical delay >60ms was considered indicative of intraventricular dyssynchrony . 16 TACT is the total duration of the atrial activation and may thus serve as a measure of severity of atrial structural remodelling and predictor of AF.23 TACT was determined by trans-thoracic echocardiography, the time from initiation of the electrocardiographic P-wave (lead II) to the local lateral left atrial activation time.23 This was measured by placing the sample volume in the left atrial basal portion, and measuring the time between initiation of the electrocardiographic P-wave and the peak velocity by tissue velocity imaging. (figure 1) TACT could only be measured in the presence of SR at baseline, and was not assessed in patients treated with amiodarone, since amiodarone may prolong the TACT, leaving 58 patients with an adequate TACT measurement. Coronary angiography was performed prior to implantation in all patients to exclude causes of heart failure amenable to surgery or intervention. Peak oxygen consumption and the anaerobic threshold were determined at baseline. Glomerular filtration rate was computed using the simplified Modification of Diet Renal Disease equation. 
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Figure 1 (II) ,, ,J\ ;' \ : \ - '6 �-0 , f \ t\ I \ O.IJ / J \ \j\ ◄ :•.11 -I.II -a.o Measurement of the Total Atrial Activation Time Atrial Fibrillation and CRT V(crn s) -0. 13 ,,/'\ / ' / . I i\J \ f I l / J * time between initiation of the electrocardiographic P wave (lead II) and the peak velocity left atrial basal portion. 
Follow-up. All patients were routinely seen every 6 months at the outpatient department. At all visits, patient history, medication use, physical examination, ECG, pacemaker interrogation, thransthoracic echocardiography, a radionuclide scan and exercise test were performed. At each CRT interrogation, data was stored both on computer disc and in a computerized ICD medical record database of the University Medical Center Groningen. A consistent protocol to standardize CRT and I CD programming was used, in which there were no systemic differences in the programming between patients with AF and SR. In most patients the device was programmed in the DDD-R mode with an AV delay of 1 1 0 ms, in case of permanent AF in the VVI-R mode. The lower rate was programmed at 60 beats per minute and the upper rate was programmed according to the upper heart rate during exercise testing. Cumulative percentages of ventricular pacing were recorded in the CRT device as the total number of ventricular paced beats in proportion to the total number of beats during the device's life. Duration of follow-up was computed from the time of CRT implantation until death or heart transplantation when applicable, or to the date when the last follow-up data were obtained. Determination whether patient is a responder or non-responder is based on the LVESV measured by an independent examiner blinded for the clinical response of the patient at six months follow-up. 
27 
Chapter 1 AF therapy. AF was treated according to a rhythm control strategy depending on complaints related to AF and ventricular rate during AF. 24 In case of paroxysmal or persistent AF in the presence of symptoms (worsening of heart failure, palpitations), or too high ventricular rate to allow optimal ventricular pacing, a rhythm control strategy was adopted including electrical cardioversions if needed and institution of antiarrhythmic drugs: sotalol (160-240 mg) daily or amiodarone (200 mg daily after 4 weeks of loading with 600-800 mg daily). If AF was accepted, rate control was carefully instituted aiming at optimal biventricular pacing. Statistical analysis. Baseline descriptive statistics are presented as the mean ± standard deviation or median (range) for continuous variables and numbers with percentages for categorical variables. Differences between variables in patients in the responders versus those that did not respond were evaluated by Students t-test or Mann-Whitney U-test, depending on normality of the data, for continuous data, Fisher exact test or Chi-square test for categorical data. We calculated adjusted odds ratios (OR) of clinical characteristics, baseline drug therapy, and device characteristics with logistic regression, to identify predictors of CRT response. Linearity of the continuous variables with respect to the response variable was assessed by determining the quartiles of their distribution. Thereafter, OR for each quartile were calculated. In case of a linear trend in the estimated OR's, the variable was introduced in the model as continuous. If no linearity was shown, the variable was further categorized by taking together the quartiles with OR's similar in magnitude, primarily the median value or otherwise based on clinical relevance. Multivariate analysis was performed using all variables with p<0. 10 in univariate analysis. A stepwise approach was used. The final model included all variables with p<0.05; variables with p�0.05 in the multivariate model were excluded. Interaction was investigated. In all analysis p<0.05 was considered statistically significant. RESULTS Patient characteristics. We included 114 patients of whom 56 (49%) were known with AF (23 current AF, 33 earlier AF). The other 58 patients had no history of AF. Of the patients with AF, 19 (34%) had earlier paroxysmal AF, 31 (55%) (earlier) persistent AF and 6 (11 %) were in permanent AF. The patient characteristics at baseline are shown in Table 1. Patients with AF had a higher diastolic blood pressure, a larger right atrium, a more impaired right ventricular function and more often had undergone previous cardiac surgery. 
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Atrial Fibrillation and CRT Tabel 1. Baseline characteristics patients with and without AF Total population AF No-AF P-, ,1l uc Age (years) Male (n= 1 1 4) (n='i6) (n='i8)  63±11 63±11 62±12 85(75%) 39(70%) 46(79%) Total AF duration (days) 1 ,330(1 5-9887) 1 ,330(1 5-9887) Type of AF Paroxysmal AF 1 9(17%) 19(34%) Persistent AF 31 (27%) 31 (55%) Permanent AF at baseline 6(5%) 6(11 %) Current AF duration (days) 398(2-3449) 398(2-3449) NYHA class for heart failure II 9(8%) 6(11 %) 3 (5%) III 95 (83%) 45(80%) 50(86%) IV 10 (9%) 5 (9%) 5 (9%) Coronary Artery Disease 50(44%) 21 (38%) 29(50%) Non ischemic cardiomyopathy 64(56%) 35 (63%) 29(50%) Previous cardiac surgery 38 (33%) 24(43%) 14(24%) Diabetes Mellitus 1 8(16%) 7(13%) 11 (1 9%) Hypertension 35(31 %) 19(34%) 16(28%) Systolic blood pressure 119±20 121 ±19  116±22 Diastolic blood pressure 71±10 74±9 61±19 Crea ti nine ( umol/1) 112(71-307) 112(71-235) 113(74-307) eGFR (ml/min/1 .73 m2) 62±19 62±18 61±19 QRS duration (ms) 1 68±33 165±35 170±30 LBBB 72(63%) 30(54%) 42(72%) LVEF 23±8 23±8 23±8 Left atrial, long axis (mm) 49(31-86) 51 (31-86) 47(32-66) Left atrial, apical view (mm) 69(42-93) 70(51-93) 67(42-80) Right atrial length (mm) 59(35-87) 62(40-87) 58(35-78) LVEDV (ml) 212±70 214±75 211 ±65 LVESV (ml) 1 63±63 163±63 162±63 MV regurgitation (#) 22(19%) 1 5 (27%) 7(12%) TI regurgitation (#) 6(5%) 3(5%) 3(5%) QRS AV opening (ms) 1 67±40 168±38 169±38 QRS PV opening (ms) 1 34±29 130±30 130±30 IVMD > 40 ms 53(46%) 24(43%) 29(50%) SL > 60 ms 44(39%) 20(36%) 24(41 %) TACT (ms) 1 51 ±28 1 58±31 148±26 Peak VO2 (ml/min/kg) 14(4-42) 14(4-42) 14(5-32) Medication ACE/ARB 1 06(93%) 54(96%) 52(90%) �-Blocker 83(73%) 38(68%) 45(78%) Diuretics 1 06(93%) 51 (91%) 55 (95%) Digoxin 23(20%) 14(25%) 9(1 6%) Amiodarone 31 (27%) 20(36%) 1 1 (1 9%) ACE=angiotensine converting enzyme; AF=atrial fibrillation; ARB=angiotensine receptor 0.50 0.24 0.54 0.1 8 0.1 8 0.03 0.34 0.46 0.26 0.002 0.98 0.97 0.41 0.1 0 0.66 0.10 0.06 0.03 0.82 0.93 0.05 0.95 0.81 0.1 8 0.43 0.79 0.21 0.74 0.1 6 0.24 0.43 0.21 0.05 blocker; AV=aortic valve; DM=diabetes mellitus; eGFR=estimated Glomerular filtration rate; LBBB=left bundle branch block; LVEDV=left ventricular end diastolic volume; LVEF=left ventricular ejection fraction; LVESV =left ventricular end systolic volume; IVMD=inter ventricular mechanical delay; MV =mitral valve; NYHA=New York Heart Association; PV =pulmonary valve; RV= right ventricle; TACT =total atrial conduction time; TV =tricuspidalis valve. # = moderate or severe 29 
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Chapter 1 Tabel 2 .  Baseline characteristics responders versus non-responders in patients with AF Age (years) Male Total AF duration (days) Paroxysmal AF history Persistent AF history Permanent AF at baseline Current AF duration (days) NYHA class for heart failure II III IV Coronary Artery Disease Non ischemic cardiomyopathy Diabetes mellicus Hypertension Systolic blood pressure Diastolic blood pressure Creatinine ( umol/1) eGFR (ml/min/1 .73 m2) QRS duration (ms) 
LBBB LVEF Left atrial, long axis (mm) Left atrial, apical view (mm) Right atrial length (mm) LVEDV (ml) LVESV (ml) Septum (mm) Posterior (mm) MV regurgitation (#) TI regurgitation (#) QRS AV opening (ms) QRS PV opening (ms) IVMD >40 ms SL >60 ms TACT (ms) Medication ACE/ARB �-Blocker Diuretics Digoxin Amiodarone Abbreviations as in Table 1 .  # moderate or severe 32 Total populat ion Responder Non-responder P-value (n=56) (n=.n) ( n=24) 63±11 63±12 64±10 39(70%) 22(69%) 17 (71 %) 1 ,330(1 5-9887) 1 ,897(1 5-9887) 1 ,077(108-7372) 1 9 (34%) 11 (34%) 8 (33%) 31 (55%) 1 9(59%) 1 2(50%) 6(11 %) 2(6%) 4(17%) 398(2-3,449) 320(63-2,947) 688(2-3,499) 6(1 1  %) 4(13%) 2(8%) 45 (80%) 23(72%) 22(92%) 5 (9%) 5 ( 16%) 0 (0%) 21 (38%) 12(38%) 9(38%) 35 (63%) 23(72%) 1 2(50%) 7(13%) 1 (3%) 6(25%) 19 (34%) 10 (31 %) 9(38%) 121±1 9  1 22±18 11 9±20 74±9 74±8 74±10 112(71-235) 112(71-235) 112(82-172) 62±1 8 62±19 61±17 1 65±35 164±33 1 66±39 30(54%) 17(53%) 1 3(54%) 23±8 23±9 22±7 51 (31-86) 50(31-86) 52(31-79) 70(51 -93) 69(51-92) 70(54-93) 62(40-87) 64(43-80) 62(40-87) 214±75 212±78 2 17±47 1 63±63 1 65±64 1 61 ±63 1 0±2 1 0±2 1 0±2 9±2 9±2 9±2 1 5 (27%) 10 (31 %) 5 (21 %) 3(5%) 1 (3%) 2(8%) 160(79-252) 1 80(91-252) 1 60(78-230) 137(86-233) 136(97-180) 1 60(86-233) 24(43%) 1 9(59%) 5 (21 %) 20(36%) 1 5 (47%) 5 (21 %) 1 58±31 137±20 1 86±16 54(96%) 31 (55%) 23(96%) 38(68%) 22(69%) 16 (67%) 51 (91%) 30(94%) 21 (88%) 14(25%) 7(22%) 7(29%) 20(36%) 1 1 (34%) 9(38%) 0.53 0.87 0.65 0.39 0.10 0.09 0.09 O.Ql 0.63 0.46 0.95 0.89 0 .84 0.83 0.1 5 0 .82 0.1 8 0.37 0.90 0.83 0.81 0.26 0.28 0.38 0.41 0.89 0.89 O.Ql 0.05 <0.001 0 .84 0.87 0.42 0.53 0 .81 
Atrial Fibrillation and CRT A 
IVMD > 40 ms 
TACT < 1 52 mm 
-50 50 1 00 1 50 
Non response Response B 
NICMP I I 
Creatinine < 1 1 3  (umol/1) 
Systolic BP > 1 1 6  (mmHg) 
Posterolateral lead postion I I 
-20 20 40 60 80 1 00 
Non response Response Figure 3 Multivariate analysis with regard to response to CRT in patients with (panel A) and without AF (panel B) AF during follow-up. A total of 35 (62%) patients in the AF group versus 14 (24%) patients in the no-AF group (p=<0.0001) had AF during follow-up. At the time of implantation of the CRT device 23 patients had AF. After testing of the ICD a total of 11 of the 23 patients (48%) with AF at baseline converted to sinus rhythm. Nine of these patients suffered from a recurrent episode of persistent AF during follow up and underwent another ECV during. Only 2 of them remained in sinus rhythm during follow up. Of the patients with a history of paroxysmal or persistent AF but sinus rhythm at baseline, 6 patients developed persistent AF and 8 developed paroxysmal AF during follow up. More patients with previous persistent AF developed AF during follow up (8 patients [47%] versus 6 [32%] with persistent versus paroxysmal AF prior to implantation, respectively). The AF burden during follow up was low in patients with prior paroxysmal AF: a median of 0% (0-60%). In the non responders the AF burden was O % (0-60%) versus 0% (1-9%) in the responders. The AF burden in the patients with prior persistent AF was 2 [0-100] ( 1  [0-100] versus 16 [0-100] in responders versus non responders). 
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Chapter 1 In the no-AF group 14 (24%) patients had AF during follow up. The AF burden as measured by the device was statistically different between patients with a history of AF and those with no history of AF (26% [0-100%] versus 0% [0-64%] , p<0.001). At the end of follow-up 17 (30%) versus 3 (5%) patients in the AF versus no-AF group were in permanent AF (p<0.0001). (Figure 
4) New onset AF during follow-up (14 of 58 patients with no previous AF) was associated with a lower response (4 [29%] responders versus 10 [71 %] non-responder, respectively, p=0.02). In patients with a history of AF and SR at baseline, the TACT at baseline was barely longer in those who developed AF during follow-up (173±26 versus 146±26, respectively p=0.05). (Figure 5) This difference was not observed in patients with no history of AF. TACT predicted success of CRT in patients with a history of AF. In these patients, TACT was significantly higher in non­responders (186± 16 msec versus 137±20 msec, p<0.001). A l 50 
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Figure 4 Percentage of AF burden in patients with (panel A) and without AF (panel B), responders and non­responders. 34 
Atrial Fibrillation and CRT 
Correlation TACT and AF burden FU Correlation TACT and AF burden 
A 146±30 173±26 B 146±23 157±36 
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No history of AF Figure 5 Relation between TACT and AF burden during follow-up in patients with (panel A) and without AF (panel B) * p=0.05 DISCUSSION Our study demonstrates that response to CRT is comparable between patients with current and earlier AF and SR patients. New onset AF, however, was associated with failure to CRT. Furthermore, the study shows that predictors for response are different in AF and SR patients. TACT may be a parameter to predict response in patients with a history of AF. Prevalence of AF in CRT patients. In heart failure patients, the occurrence of co-existent AF is strongly related to the underlying NYHA functional class. The prevalence of AF is 5% for NYHA functional class I, 10% to 25% for class II to III, and as high as 50% for class IV:2 For heart failure patients who are still in SR, the annual incidence of AF is approximately 5%. The development of AF is difficult to predict, but the risk is greatest in those with atrial conduction delay or evidence of atrial mechanical dysfunction , both markers of the presence of a substrate for AF. 25•26 In our study 49% of patients 
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Chapter 1 had either earlier or current AF and another 24% developed new onset AF during follow-up. These figures are somewhat higher than previously reported, even for NYHA III patients. This may relate to the fact (a) that we also included patients with previous AF but sinus rhythm at baseline, and (b) that new AF was carefully documented by the implanted device. Hoppe et al. reported an incidence of AF in 66 of 409 (16%) versus 58 of 404 (14%) patients who received CRT versus medical therapy, respectively, during a follow-up of 29 months. These figures are lower then ours. In their study, however, AF was only documented by electrocardiograms, and in contrast to our study, not by the device. 19 It undoubtedly underscores the importance of AF in patients treated with CRT. Unreliable pacing may occur due to absence of AV-synchrony and too high ventricular rates . 
Response to CRT. In the present study response to CRT was equal in patients with and without AF and in patients with current and earlier AF. Yet, only limited evidence is available about success of CRT in patients with AF. It is suggested that CRT is effective in patients with AF. On an individual basis, however, the response to CRT may be lower in patients with AF as compared to patients in SR. Patients who had undergone an AV-node ablation more frequently responded to CRT since that intervention guaranteed successful pacing almost continuously. 1 3•15 In our study only 1 patient underwent AV-node ablation. An important finding is that we observed that new onset AF, in contrast to the presence of AF at baseline, was associated failure to CRT. It is difficult to determine whether new onset AF post CRT is a consequence or a cause of haemodynamic deterioration, i.e. failure to CRT. On one hand, AF post CRT may reduce effective biventricular pacing, due to high heart rates during AF, leading to failure to CRT. On the other hand, deterioration of the haemodynarnic situation may also induce AF. In addition, we do not know whether new onset AF patients were nevertheless better with CRT as they would have been without CRT. The group of Bax et al. were the first to describe this issue. 13• 1 5 This finding implies that during follow-up the presence of AF should be carefully monitored as it either may be a marker of deterioration of the haemodynamic situation due to progression of the disease, or, the other way around, may eventually lead to an impaired haemodynamic situation.27 Response rate in our study was significantly higher when an improvement of � 1 NYHA class was evaluated. In accordance with our data, other studies found a poor relation between clinical response and echocardiographic response to CRT. 28 
Predictors for response. Many studies investigated predictors for response to CRT in SR patients. To a lesser extent this has been investigated in AF patients. Our data reveal that predictors for successful CRT in AF patients are a longer duration of the TACT and a long IVMD. Univariately, also typical predictors 36 
Atrial Fibrillation and CRT for success of CRT, like septal to lateral dyssynchrony and non-ischemic cardiomyopathy were associated with response. The finding that TACT influences response to therapy is new and may be used to predict response. Clearly, research has to be performed to assess its definite significance. The risk of AF is greatest in those with atrial conduction delay or evidence of atrial mechanical dysfunction, i.e. in the presence of markers for the presence of a substrate for AF.25-26 TACT is the total duration of the atrial activation and may thus be a measure of severity of structural remodelling, i.e. the presence of a substrate of AF. The technique to assess atrial activation time has recently been introduced by Merckx et al.23 They could demonstrate a good correlation with the golden standard for total atrial activation time, the signal average electrocardiogram. Clearly, it may not be concluded from the present findings that the typical predictors for response to CRT are of no value in patients with AF. In patients with no-AF, predictors for response were different. Non-ischemic cardiomyopathy, lower creatinine plasma levels, and higher systolic blood pressure determined success. The TACT did not coincide with response in the no-AF patients. The fact that patients with and without AF have different predictors for response has not been described before. Previous studies in especially SR patients observed that a more prolonged IVMD, non-ischemic cardiomyopathy, a smaller left ventricular end systolic diameter, lower systolic blood pressure, a septal to lateral delay of >60ms and/or left ventricular and right ventricular lead position were associated with higher response to CRT. 16•29-3 1  Possible the TACT plays a more important role in AF patients because these patients are at a greater risk for developing AF burden during the follow-up. AF burden during follow-up. Indeed, AF during CRT occurred more frequently in patients known with previous AF. During a mean follow-up of 18 months 62% of these patients had additional AF episodes during CRT. This figure was significantly lower (24% of the patients) in patients without previous AF. Previous studies reported the occurrence of AF between 16% and 38% depending on duration of follow­up and presence of earlier AF. 1 9•20 This relatively high percentage of AF at least in part relates to the definition used (any AF documented on an ECG, Holter monitoring or detected by the device with a duration >30 seconds). Limitations. This is an observational study and is affected by all the limitations of these studies. On the other hand, because of a prospective real-time database implementation, we have minimal missing data, and all our patients are consecutive, which limits possible patients selection bias. 37 
Chapter 1 
Conclusion. The present study notifies that the development of new-AF is associated with lower success of CRT, possible due to inadequate rate control. Furthermore, it signifies that predictors for response to CRT are different between AF and sinus rhythm patients and introduces a new predictor for response of CRT in AF patients, the total atrial activation time. 
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Atrial fibrillation does not influence long-term response to cardiac resynchronization therapy 
Chapter 2 STRUCTURED ABSTRACT 
Aim. Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure and sinus rhythm. Its value in atrial fibrillation (AF) is less well established. Our aim was to investigate the influence of AF on short- and long-term response and prognosis in patients treated with CRT. 
Methods. We examined consecutive patients in whom CRT was implanted disregarding the atrial rhythm. Atrial fibrillation was defined as either current or earlier AF. Both patient groups were evaluated for long-term response to CRT, hospitalization for heart failure and all-cause mortality. 
Results. We included 214 heart failure patients, 94 ( 44%) with AF ( 42 current and 52 earlier). Mean follow­up was 27 ± 15 months. Atrioventricular junction ablation was performed only if pharmacological rate control therapy failed (n=8 patients). Echocardiographic response at 6 months, 1 year and 2 years was comparable between patients with and without AF (66%, 73% and 65% versus 64%, 7 1 % and 63%, respectively). The incidence of all-cause mortality or hospitalization for heart failure was also similar in AF versus no-AF patients, 27 (29%) versus 39 (33%), p=0.55. This also holds for the cumulative event rates of all-cause mortality and/or hospitalization for heart failure (log-rank p-value 0.54). 
Conclusion. Short- and long-term echocardiographic response, heart failure hospitalizations and all-cause mortality are similar in AF and SR patients, even with atrioventricular junction ablation in a minority of patients. 
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AF and CRT INTRODUCTION Cardiac resynchronization therapy (CRT) is now a well established treatment for patients with pharmacological refractory heart failure with prolonged QRS, low ejection fraction and sinus rhythm. 1-3 CRT on top of optimal pharmacological treatment is associated with approximately 40% relative reduction in all-cause mortality. 1 • 2 However, patients with atrial fibrillation (AF) are not well represented in the landmark trials that established the clinical benefit of CRT. 4• 5 This is a limitation, especially since heart failure and AF frequently coexists.6• 7 In patients with AF who receive CRT, the effectiveness of CRT may be reduced due to high intrinsic ventricular rate response, precluding effective biventricular pacing. 8 Some studies have shown beneficial effects of CRT in patients with AF.9• 10 It has been suggested, however, that CRT is only effective after atrioventricular junction (A VJ) ablation. 1 1 • 12 To further elucidate the role of CRT in AF patients and whether AVJ ablation is necessary in all patients we performed this study. The aims of this study were to prospectively assess the short- and long-term effects of CRT on (1) ventricular function and reverse remodeling, and (2) the occurrence of the clinical endpoints (hospitalization for heart failure and all-cause mortality). METHODS Patient population. The population consisted of 214 consecutive patients with congestive heart failure receiving CRT. Response was defined as a decrease of 10% or more in left ventricular end systolic volume (LVESV) after 6 months of follow-up. Our protocol has been described before. 13• 14 In short, baseline parameters were assessed, including patient history, physical examination, 12 lead electrocardiogram, transthoracic echocardiography, exercise testing, radionuclide scanning and coronary angiography. The left ventricular end diastolic volumes (LVEDV) and end systolic volumes (LVESV) were measured using the modified biplane Simpson method using the apical four-chamber and two-chamber views. 1 5 All patients were routinely seen every 6 months at the out patient department. Clinical status was assessed, CRT interrogated, a transthoracic echocardiogram, radionuclide scan for left ventricular ejection fraction determination, and an exercise test (maximal oxygen consumption) were performed. To investigate the role of AF with regard to response and outcome, AF prior to implantation was carefully documented. In case of AF, device interrogation was performed every 3 months to ensure optimal biventricular pacing, defined as > 85% biventricular pacing. 12 Specific attention was paid to the heart rate response during an exercise test. 8 In case of inadequate biventricular pacing due to AF despite optimal pharmacological rate control, patients 45 
Chapter 2 were scheduled for an atrioventricular junction ablation. Atrial fibrillation was defined as any AF documented on an electrocardiogram (ECG), holter monitoring (duration > 30 seconds), or detected by the CRT (high atrial rate > 200 bpm, duration > 30 seconds). 1 3 When AF terminated spontaneously within 7 days it was designated paroxysmal. If it sustained beyond 7 days it was classified as persistent AF, independent of pharmacological therapy or direct-current cardioversion. If cardioversion failed or was not attempted AF was defined as permanent AF. 1 6  The clinical endpoint, i.e. outcome was defined as all-cause mortality, cardiac transplantation and heart failure requiring hospitalization. Dates of events and the most recent event-free follow-up were obtained for all patients by chart review. Patients who underwent cardiac transplantation were censored at the time of transplantation as death. Statistical analysis. Baseline descriptive statistics are presented as the mean ± standard deviation (SD) or median (range) for continuous variables and numbers with percentages for categorical variables. Differences between variables were evaluated by Students t-test or Mann-Whitney U-test, depending on normality of the data, for continuous data, Fisher exact test or Chi-square test for categorical data. Kaplan-Meier estimates were performed to study the occurrence of the clinical endpoint (hospitalization for heart failure, or all cause mortality) during follow-up in the study population. Adjusted hazard ratios (HR) were calculated using Cox proportional hazards regression models. Linearity of the continuous variables with respect to the response variable was assessed by determining the quartiles of their distribution. Thereafter, HR's for each quartile were calculated. In case of a linear trend the variable was introduced in the model as continuous. If no linearity was shown, the variable was further categorized by taking together the quartiles with HR's similar in magnitude, primarily the median value or otherwise based on clinical relevance. Multivariate analysis was performed using all variables with p<0. l 0 in univariate analysis. A stepwise approach was used. The final model included all variables with p<0.05 ; variables with p�0.05 in the multivariate model were excluded. Interaction was investigated. In all analyses p<0.05 was considered statistically significant. 46 
AF and CRT RESULTS Patient characteristics. We included 214 patients, 94 (44%) had AF (42 current AF and 52 earlier AF) and 120 patients had no history of AF. The patient characteristics at baseline are shown in Table 1 .  Patients with AF had significantly larger right and left atria, a more impaired right ventricular function, and more often undergone previous cardiac surgery. AVJ ablation was performed in 8 AF patients. In 4 patients this was done to ensure adequate biventricular pacing a median of 10 months (2-18 months) after CRT implantation. The other 4 patients had already undergone an atrioventricular junction ablation before upgrade to CRT due to untreatable complaints related to AF. 47 
Chapter 2 Table 1. Baseline characteristics patients with and without atrial fibrillation Toc,11 populacion AF No-AF P-valuc Age (years) Male, No. (%) Total AF duration (days) Type of AF Paroxysmal AF, No. (%) Persistent AF, No. (%) Permanent AF, No. (%) Current AF duration (days) NYHA class for heart failure III, No. (%) IV, No. (%) Non ischemic cardiomyopathy, No. {%) Coronary artery disease, No. (%) Previous cardiac surgery, No. (%) Diabetes Mellitus, No. (%) Hypertension, No. (%) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) eGFR {ml/min/1 .73 m2) QRS duration (ms) LBBB, No. (%) LVEF (%) Left atrial, long axis (mm) Left atrial, apical view (mm) Right atrial, length (mm) Left atrial volume (ml) LVEDV (ml) LVESV (ml) RV-TAPSE (mm) MV regurgitation (#), No. {%) TV regurgitaton {#), No. (%) IVMD > 40 ms, No. (%) Septal to lateral delay > 60 ms, No. (%) Medication ACE/ARB, No. {%) B-blocker, No. (%) Diuretics, No. (%) Digoxin, No. (%) Amiodarone, No. (%) Oral anticoagulation, No. {%) (n=2 1 4) (n�94) (n= 1 20) 64±11 65±1 0 63±12 1 59 (74) 69 (73) 90 (75) 1 ,802 (1 5-1 5,891 ) 1 ,802 (1 5-1 5 ,891) 26 (12) 26 (28) 55 (26) 55 (59) 13 (6) 13 (14) 398 (2-4,279) 398 (2-4,279) 1 99 (94) 89 (95) 111 (92) 14 (6) 5 (5) 9 (8) 1 09 (51) 54 (57) 55 (46) 105  (49) 40 (43) 65 (54) 77 (36) 44 (47) 33 (28) 41 (1 9) 15 (16) 26 (22) 77 (36) 35 (37) 42 (35) 11 9±19 120±19 119±11 72±11 73±9 71±11 67±21 63±23 64±22 1 65±31 1 66±32 165±30 149 (70) 59 (63) 90 (75) 23±8 23±8 23±9 49 (30-86) 50 (31-86) 47 (30-66) 67 (42-93) 69 (51 -93) 65 (42-85) 59 (35-87) 61 (40-87) 57 (35-78) 62 (14-333) 69 (16-333) 51 (14-1 50) 234 (75-641) 233 (45-464) 234 (89-641) 1 77 (59-564) 178 (56-497) 178 (58-564) 1 7±5 16±5 1 8±5 51 {21 ) 25 (27) 26 {22) 1 9  (8) 1 2  (13) 7 (6) 78 (36) 32 (34) 46 (38) 1 07 (50) 45 (48) 62 (52) 1 94 (90) 89 (95) 105 {88) 1 78 (83) 76 (81) 102 (85) 196 (91 ) 85 (90) 111  (93) 39 (1 8) 25 (27) 1 5  (1 3) 48 (22) 30 (32) 18 (1 5) 1 68 (79) 84 (89) 84 (70) 0.36 0.79 0.73 0.09 0.09 0.003 0.30 0.73 0.68 0.06 0.71 0.77 0.04 0.74 0.008 0.005 0.003 O.ol 0.58 0.68 0.04 0.40 0.08 0.62 0.79 0.05 0 .54 0.61 0.01 0.003 0.001 ACE = angiotensin converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; eGFR 
= estimated Glomerular filtration rate; IVMD = interventricular mechanical delay; LBBB = left bundle branch block; LVEF= Left ventricular ejection fraction; LVEDV = Left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; MV = mitral valve; NYHA = New York Heart Association functional classification; RV = right ventricular; TV = tricuspid valve # moderate or severe, Data are described as mean ± SD, or median {range) 48 
AF and CRT Response to therapy. Echocardiographic response was 65%, 72% and 63% after 6 months, 1 year and 2 years, respectively. The response rate during follow-up was comparable between patients with current and earlier AF (64%, 76% and 68% versus 67%, 70% and 63%, respectively, all not significantly different) and between patients with and without AF (66%, 73% and 65% versus 64%, 7 1  % and 63%, all not significantly different). (Figure 1) Percentages of biventricular pacing was> 85% in the majority of AF and SR patients (89 [95%] versus 115 [96%] , p=0.63). 
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54 Figure 4 Kaplan-Meier Curves for the composite endpoint (hospitalization for heart failure and/ or all-cause mortality) (A), hospitalization for heart failure (B) , and all-cause mortality (C) . Predictors of all-cause mortality and outcome. Predictors for hospitalization for heart failure or all-cause mortality were non-response (HR 2.6 [ l . 5-4.4] , p<0.000 1 ) , a larger left atrium (HR 3.2 [ l .8-5.8] , p<0.000 1 )  and a thinner posterior wall (HR 3.0 [ 1 .8-5.2] , p<0.000 1 ). (Table 3) The presence of current or earlier AF did not in influence the outcome. 
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AF and CRT Table 3 .  Multivariate analyses total population- predictors for hospitalization for heart failure or all-cause mortality Non-responder LA length > 65 mm LV posterior wall diameter < 9 mm Systolic blood pressure < 120 mmHg RA length > 59 mm LV septa! wall diameter < 9 mm LA volume > 60 ml TV regurgitation eGFR < 67 ml/min/1 .73m2 Univariate Analyses Multivariate Analyses HR (95% CI) P value HR (95% CI) P value 2.8 ( 1.7-4.6) <0.0001 2.6 (1 .5-4.4) <0.0001 2.9 (1 .6-5 .1) 0.0001 3.2 (1 .8-5 .8) <0.0001 2.3 (1 .4-3.9) 0.001 3.0 ( 1.8-5 .2) <0.0001 1 .9 (1 .2-3.1) 0.01 1 .95 (1 .2-3.3) 0.01 1 . 8  (1.1 -3.0) 0.03 1 .7 (1 .1-3.0) 0.05 2.2 (1 .0-4.6) 0 .04 1 .6 (1 .0-2.7) 0.06 eGFR = estimated Glomerular filtration rate; LA = left atrial, LV = left ventricular; RA = right atrial; TV = tricuspid valve. DISCUSSION. Our study demonstrates that long-term response to CRT is comparable between patients with AF and sinus rhythm. In addition, we observed no difference between AF and sinus rhythm patients with respect to the clinical endpoint (all-cause mortality or hospitalization for heart failure) and clinical improvement. Prevalence of atrial fibrillation in cardiac resynchronization therapy patients. In heart failure patients, the occurrence of co-existent AF is strongly related to the underlying NYHA functional class. The prevalence of AF is 5% for NYHA functional class I, 10-25% for classes II and III, and as high as 50% for class IV:7 Due to the absence of AV-synchrony and too high ventricular rates unreliable pacing may occur in AF patients treated with CRT and this may preclude response to CRT. In our study, 44% of the patients had either earlier or current AF. This percentage of AF patients is relatively high compared to others, who observed ranges between 14% to 37%.4• 1 0- 12, 1 7• 1 8  The higher prevalence in our group may relate amongst others to the fact that we very carefully investigated whether patients were known with AF or not. It clearly highlights the importance of AF in CRT. Response to cardiac resynchronization therapy in AF versus sinus rhythm patients. In line with data from others, we observed a long term improvement of cardiac function. 1 1 • 1 2• 
17• 19 This improvement was similar in patients with and without AF. In contrast to our results, previous studies found that AF was associated with a significantly lower response to CRT.4• 1 1 • 1 2• 55  
Chapter 2 18 Gasparini et al. and Ferreira et al. described that response in AF patients was only comparable 
to sinus rhythm patients if AVJ ablation was performed in AF patients. 1 1 • 1 2• 18 The necessity of AVJ ablation, however, is contradicted by our data and that of others, which show that if adequate pharmacological rate control during AF is achieved, ensuring optimal biventricular pacing, outcome between AF and sinus rhythm patients is comparable. 10• 17 Nevertheless, new onset AF may reduce response to CRT as has been demonstrated recently.20 Atrial fibrillation and outcome. At present it is unsettled whether AF impairs outcome. Evidence suggests that not the arrhythmia but the underlying heart disease determines prognosis.21  In the present study we observed no significant difference in the clinical endpoint heart failure hospitalizations and all-cause mortality between AF and sinus rhythm patients. Until now, there are only a limited number of studies on outcome in patients with AF treated with CRT, and in most studies AVJ ablation was routinely performed, 1°, 12• 17• 18 Some studies observed that AF patients without an AVJ ablation had a significantly higher cardiovascular morbidity and all-cause mortality rate. 12• 18 In those studies, however, the percentage of biventricular pacing was low. Almost half of the AF patients had less than 85% of biventricular pacing. 1 2  In contrast, in our study only a minority necessitated AVJ ablation to ensure continuous pacing. The latter illustrates, on one hand, the difficulty and, on the other hand, that importance of optimizing rate control in AF patients, both in rest and during exercise. 8 All in all, the above suggests that in hemodynamic stable heart failure patients AF does not influence response to CRT and outcome, in contrast to new-onset AF. 20• 21 However, it requires permanent biventricular pacing, also during exercise. Predictors adverse events. In the present study we observed that a larger left atrial size predicted hospitalisations for heart failure and all-cause mortality. This points to the fact that left atrial size seems an important determinant of prognosis in heart failure.22-24 In line with the above, Yu et al. observed that an improvement in left atrial function during CRT (measured at 3 months follow-up) was associated with a better outcome.25 Limitations. This is an observational study and is affected by all the limitations of these studies. On the other hand, because of a prospective real-time database implementation, we have minimal missing data, and all our patients are consecutive which limits possible patient selection bias. Furthermore, continuous biventricular pacing was carefully monitored as described before . In case of inadequate biventricular pacing due to high ventricular heart rates AVJ ablation was performed. 56 
AF and CRT Conclusion. The present study demonstrates that both short- and long-term echocardiographic response and outcome are similar in patients with AF and sinus rhythm, even with AVJ ablation in only a minority of patients. 
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Clinical significance of new-onset atrial fibrillation during cardiac resynchronization therapy 
Chapter 3 STRUCTURED ABSTRACT Background. Atrial fibrillation (AF) and heart failure (HF) often coexist. It is unknown whether CRT prevents new-onset AF during long term follow-up and how new-onset influence response to CRT and prognosis. Methods and results. We examined 120 consecutive CRT patients without previous AF. Response to CRT was defined as a decrease in left ventricular end-systolic volume (LVESV) � 10% after 6 months. AF during follow-up was monitored by interrogation of the device (high atrial rate > 200 ms, duration >30 seconds). During a mean follow-up of26 ± 15 months 17 of 120 patients (14%) developed new­onset AF. Responders significantly less frequently had new-onset AF (5 [6%] versus 12  [28%], p=0.001). Median time to AF was 12 (11 - 18) months in responders and 11  (2-24) months in non-responders (p=0.72). Multivariate analysis revealed that permanent sinus rhythm (OR 8. 1 [ 1 .4-29.7] , p=0.02), non-ischemic cardiomyopathy (OR 5. 1 [1.5- 16.9] , p=0.008), a septa! to lateral delay> 60 ms (OR 8. 1 [2.8-13.6] , p<0.0001 )  and a higher systolic blood pressure (OR 4. 1 [ 1.3-13. 1 ] ,  p=0.02) were predictors for response to CRT. Not new-onset-AF but severity of underlying disease determined prognosis. Conclusion. Successful CRT reduces new-onset AF. New-onset AF is associated with failure of CRT but not with clinical outcome. 
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New-onset AF and CRT Atrial fibrillation (AF) is the most common arrhythmia in heart failure. 1-3 The incidence increases with its severity. It is still unknown whether AF itself impairs prognosis or whether AF is merely a marker of more severe underlying heart disease. 1 • 4-6 Recent data suggest that new-onset AF is associated with adverse prognosis.4-9 Until now, pharmacological rate versus rhythm control studies could not demonstrate any beneficial effect of a rhythm control strategy, also not in HF. 10-
1 2  These studies, however, were hampered by the fact that permanent sinus rhythm was difficult to achieve, even with amiodarone. 13• 14 New non-pharmacological therapies provide new options to prevent AF. Currently there is no consensus whether CRT may prevent new-onset AF and whether new-onset AF may influence response to CRT and prognosis. Accordingly, the aim of this prospective study was to investigate the incidence of new-onset AF, the efficacy of CRT to prevent new-onset AF and to evaluate the impact of new-onset AF on response to CRT and prognosis. METHODS Patient population. The study population consists of 1 20 consecutive heart failure patients without a history of AF who received CRT. Response was defined as a decrease of 1 0% or more in left ventricular end systolic volume (LVESV) after 6 months of follow-up. Our protocol has been described before. 1 5• 16 In short, baseline parameters were assessed, including patient history, physical examination , 1 2  lead electrocardiogram, transthoracic echocardiography, exercise testing, radionuclide scanning and coronary angiography. The left ventricular end diastolic volumes (LVEDV) and end systolic volumes (LVESV) were measured using the modified biplane Simpson method using the apical four-chamber and two-chamber views. 17 Left atrial volume was derived from the M-mode dimension assuming a spherical shape. 1 8 Follow-up. Our post implantation protocol has been described before. 1 5• 1 6  In short, all patients were routinely seen every 6 months at the out patient department. Clinical status was assessed, CRT interrogated, a transthoracic echocardiogram, radionuclide scan for left ventricular ejection fraction determination , and an exercise test (maximal oxygen consumption) were performed. To investigate the role of AF with regard to response we carefully monitored AF during follow-up. Atrial fibrillation during follow-up was defined as any AF documented on an electrocardiogram (ECG), holter monitoring (duration > 30 seconds), or detected by the device (high atrial rate > 200 bpm, duration > 30 seconds).1 5  When AF terminated spontaneously within 7 days it was designated paroxysmal. If it sustained beyond 7 days it was classified as persistent AF, independent of pharmacological therapy or direct-current cardioversion.19 Atrial fibrillation 
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Chapter 3 was treated according to a rhythm control strategy. 1 1 , 14 This included electrical cardioversions if required and institution of anti-arrhythmic drugs, sotalol (160-240 mg) daily or amiodarone (200 mg daily after 4 weeks ofloading with 600 mg daily). In case of unsuccessful rhythm control therapy AF was accepted and rate control therapy was instituted aiming at optimal permanent biventricular pacing. Specific attention was paid to the heart rate response during exercise. If indicated an exercise test was performed to determine whether additional rate control medication or AV junction ablation was needed. Statistical analysis. Baseline descriptive statistics are presented as the mean ± standard deviation (SD) or median (range) for continuous variables and numbers with percentages for categorical variables. Differences between variables in responders versus non-responders were evaluated by Students t-test or Mann-Whitney U-test, depending on normality of the data, for continuous data, Fisher exact test or Chi-square test for categorical data. Kaplan-Meier estimates were performed to study the time to events between studied groups. Adjusted odds ratios (OR) of clinical characteristics, baseline drug therapy and device characteristics were calculated using logistic regression models. For time dependent variables adjusted hazard ratios (HR) were calculated. Linearity of the continuous variables with respect to the response variable was assessed by determining the quartiles of their distribution. Thereafter, 
ORI HR's for each quartile were calculated. In case of a linear trend the variable was introduced in the model as continuous. If no linearity was shown, the variable was further categorized by taking together the quartiles with OR's similar in magnitude, primarily the median value or otherwise based on clinical relevance. Multivariate analysis was performed using all variables with p < 0.10 in univariate analysis. A stepwise approach was used. The final model included all variables with p < 0.05 ; variables with p � 0.05 in the multivariate model were excluded. Interaction was investigated. In all analysis p < 0.05 was considered statistically significant. RESULTS Patient characteristics. We included 120 patients without a history of AF. Baseline characteristics are shown in Table I .  64 
New-onset AF and CRT Table 1 .  Baseline characteristics of responders versus non-responders. Age (years) Male sex, No. {%) NYHA class, No. (%) III IV Non-ischemic cardiomyopathy, No. {%) Diabetes Mellirus, No. (%) Hypertension, No. (%) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) eGFR (ml/min/1 .73 m2) QRS duration (ms) QRS > 1 50 ms, No. (%) QRS configuration, No. (%) LBBB Ocher LVEF (%) Left atrial, long axis {mm) Left aerial, apical view (mm) Left atrial, volume (ml) Right atrial, length (mm) LVEDV (ml) LVESV (ml) RV-TAPSE (mm) MY-regurgitation#, No. (%) TV-regurgitation#, No. (%) IVMD > 40 ms, No. (%) Septal to lateral delay > 60 ms, No. (%) TACT (ms) Medication, No. (%) ACE/ARB �-blocker Diuretics Oral anti-coagulation Tor.ii population Responder Non responder P-\·,1 lue (n= 1 20) (n-=77) (n=43) 63 ± 12  63  ± 12  64 ± 12  90 (75) 52 (68) 38 {88) 111 (93) 72 (94) 39 (91) 9 (7) 5 (6) 4 (9) 55 (46) 42 (55) 13 (30) 26 (22) 13 (17) 1 3  (30) 42 (35) 30 (39) 12 (28) 1 19  ± 19  122 ± 1 8  113 ± 19  71  ± 11 72 ± 11  69  ± 12  64  ± 22 68 ± 22 58 ± 20 165 ± 30 163 ± 30 167 ± 29 93 (78 58 (75) 35 (81 ) · 90 (75) 59 (77) 31 (72) 30 (25) 18 (23) 12 (28) 23 ± 9 24 ± 9 22 ± 7 47 ± 7 46 ± 7 49 ± 7 65 ± 8 63 ± 8 69 ± 8 84 ± 30 75 ± 27 97 ± 30 57 ± 8 56 ± 8 59 ± 8 246 ± 89 1 50 ±94 140 ± 81 1 90 ± 78 192 ± 65 1 84 ± 66 18 ± 5 19  ± 5 17 ± 6 26 (22) 1 5  (1 9) 1 1  (26) 7 (6) 2 (3) 5 (12) 46 (38) 32 (42) 14 (33) 62 (52) 49 (64) 1 3  (30) 149 ± 38 147 ± 37 1 51 ± 38 1 05 (88) 77 (100) 34 (79) 1 02 (85) 67 (87) 35 (81 ) 111  (93) 71 (93) 40 (93) 84 (70) 54 (70) 30 (70) 0.66 O .Ql  0.84 0.01 0.1 0 0.21 0.02 0.1 5 0.02 0.53 0.52 0.02 0.29 0.005 0.001 0.001 0.03 0.56 0.46 0.24 0.44 0.04 0.1 4  <0.0001 0.67 0.02 0.31 0.93 0.80 ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; eGFR = estimated Glomerular filtration rate; IVMD = interventricular mechanical delay; LBBB = left bundle branch block; LVEF= Left ventricular ejection fraction; LVEDV = Left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; MI = myocardial infarction; MV = mirral valve; NYHA = New York Heart Association functional classification; RV = Right ventricle; TACT = total aerial conduction time; TV = tricuspidalis valve 65 
Chapter 3 Response to therapy. Mean follow-up duration was 26 ± 15 months. After 6, 12 and 24 months of follow-up, 77 (64%), 85 (71 %), 76 (63%) patients, respectively, were responders. The LVESV and LVEF significantly improved in responders, in contrast to a significant worsening in non-responders (Figure IA and B). Mean change in LVESV was -30%, -31 % and -42% in responders after 6, 12 and 24 months, respectively, and 28%, 22% and 41 % in non-responders, respectively. LVEF increased with 10%, 12% and 11 % in responders, respectively, and with -2%, -2% and 3% in non-responders, respectively. After 6 months of follow-up the left atrial volume had significantly decreased in responders (from 82 ± 30 ml to 73 ± 27 ml, p=0.001, Figure 2). This figure remained stable during long term follow-up (75 ± 24 and 76 ± 25, p=0.001 and 0.01, respectively. In non responders no significant change occurred. 
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Months of follow up Figure 4 New-onset AF during follow-up in responders (A) and non-responders (B) . 
Black persistent or permanent AF, 
grey Paroxysmal AF. Electrical cardioversion 24 A = amiodarone started, S = sotalol started, BB + for RC = Beta-blocker dosage increased for rate control # = Atrial fibrillation temporally accepted due to underlying cause for AF (hyperthyroidism) * symptomatic AF Predictors for new-onset AF. The only multivariate predictor for the development of AF during follow-up was a larger left atrial length at baseline (OR 3.47 [ 1.2-10.6], p=0.03). Treatment of AF. A total of 3 responders with persistent AF underwent an electrical cardioversion during follow­up, one patient required a second electrical cardioversion and prophylaxis with sotalol (Table 2, and Figure 4 A). Non-responders more often required electrical cardioversions and institution of antiarrhythmic drugs (Table 2, and Figure 4B). 69 
Chapter 3 Table 2 .  Baseline and outcome variables in all new-onset AF patients Patient Sex Age NICMP LVESV LVEF Septal LA, LA, RA, TACT BB (%) ACE Diuretic (Male) (Ye,u-s) (%) (ml) (%) to later,11 long volume length (ms) (%) (%) Baseline characteristics Responders 
1 Yes 64 No 
2 Yes 53 No 
3 Yes 55 No 
4 Yes 56 Yes 
5 No 38 No 
Mean 80% 63± 1 2  20% Non-responders 
1 Yes 79 Yes 
2 Yes 64 No 
3 Yes 66 No 
4 Yes 84 No 
5 No 77 No 
6 Yes 60 No 
7 Yes 67 No 
8 No 62 No 
9 Yes 65 No 
10  Yes 7 1  No 
1 1  Yes 58 Yes 
12 Yes 66 Yes 
Mean 83% 68±8 25% 
464 13  
3 15  18  
326 30 
259 32 
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75% 92% MD = Anti-arrhythmic drugs; AF = atrial fibrillation; ECV = electrical cardioversion; LA = left atrium; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; M = male; NICMP = non ischemic cardiomyopathy; PAP = paroxysmal AF; RA = right atrium; RC = rate control; TACT = total atrial conduction time * Increased to ensure optimal biventricular pacing 
1 no complaints and adequate rate control 
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Table 2. Continued Type of AF Time ro No. Of No of Start ADD,  or AF No.  of AF  
Treatment Persistent Persistent Persistent PAF PAF Persistent Persistent Persistent Persistent Persistent Permanent# PAF PAF PAF PAF PAF PAF AF ECV rebp�e� ,1dd i tional B B  ,1cceptcd ep isodes (months) fo1 RC 12  2 Sotalol 1 7  0 1 2  1 0 1 1  0 0 1 2  0 0 1 2  ( 1 1 - 18) 3 2 1 Sotalol 4 0 BB, dosage increased for RC* 5 2 Amiodarone 9 2 1 Sotalol 2 1  0 BB, dosage increased for RC* 22 0 0 2 0 0 7 0 0 Amiodarone 20 0 0 Amiodarone 1 8  0 0 22 0 0 BB, dosage increased for RC* 23 0 0 BB, dosage increased for RC* 
1 1  
(2-24) 
No 2 No No No No No 2 No Yes, 2 recurrence was accepted No 2 No Yes No No No No No No New-onset AF and CRT 
71 
Chapter 3 Table 3 .  Baseline characteristics of patients who maintained SR or developed AF. Age (years) Male sex, No. (%) NYHA class, No. (%) III IV Non-ischemic cardiomyopathy, No. (%) Diabetes Mellitus, No. (%) Hypertension, No. (%) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) eGFR (ml/min/1 .73 m2) QRS duration (ms) QRS > 1 50 ms, No. (%) LVEF (%) Left atrial, long axis (mm) Left atrial, apical view (mm) Left atrial, volume (ml) Right atrial, length (mm) LVEDV (ml) LVESV (ml) RV-TAPSE (mm) MY-regurgitation, No. (%) TV-regurgitation, No. (%) IVMD > 40 ms, No. (%) Septal to lateral delay > 60 ms, No. (%) TACT (ms) Medication, No. (%) ACE/ARB �-blocker Diuretics Oral anti-coagulation Total population Persistent SR AF P-valuc (n= 1 20) (n= 1 03) (n= l 7) 63 ± 12 63 ± 12 64 ± 1 1  90 (75) 76 (74) 14 (82) 1 1 1  (93) 96 (93) 1 5  (88) 9 (7) 7 (7) 2 ( 12) 55 (46) 48 (47) 7 (41 )  26 (22) 20 ( 19) 6 (35) 42 (35) 38 (37) 4 (24) 1 1 9 ± 1 9  1 1 9 ± 1 9  1 1 6 ± 2 1  71  ± 1 1  70 ± 11  73  ± 15  64 ± 22 65 ± 22 6 1  ± 1 9  1 65 ± 30 164 ± 30 17 1  ± 29 93 (78) 80 (78) 13 (76) 23 ± 9 24 ± 9 23 ± 8 47 ± 7 47 ± 7 48 ± 6 65 ± 8 65 ± 9 69 ± 7 84 ± 30 8 1  ± 30 88 ± 22 57 ± 8 57 ± 8 59 ± 8 246 ± 89 241 ± 82 274 ± 1 00 1 90 ± 78 1 90 ± 66 2 17  ± 90 1 8  ± 5 1 8  ± 6 1 9  ± 3 26 (22) 23 (22) 3 ( 1 8) 7 (6) 7 (7) 0 46 (38) 40 (39) 6 (35) 62 (52) 57 (55) 5 (29) 149 ± 38 149 ± 37 147 ± 40 1 05 (88) 92 (89) 13 (76) 1 02 (85) 89 (86) 13 (76) 1 1 1  (93) 95 (92) 1 6  (94) 84 (70) 71 (69) 1 3  (76) 0.9 1 0.45 0.21 0.68 0. 1 5  0.27 0.6 1 0.3 1 0.48 0.35 0.86 0.77 0.78 0.05 0.46 0.38 0. 17  0. 1 6  0.67 0.66 0.27 0.53 0.03 0.82 0. 1 0  0.30 0.88 0.60 ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; eGFR = estimated Glomerular filtration rate; IVMD = interventricular mechanical delay; LBBB = left bundle branch block; LVEF= Left ventricular ejection fraction; LVEDV = Left ventricular end diastolic volume; LVESV = left ventricular end systolic volume; MI = myocardial infarction; MV = mitral valve; NYHA = New York Heart Association functional classification; RV = Right ventricle; TACT = total atrial conduction time; TV = tricuspidalis valve 
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New-onset AF and CRT Long-term prognosis. During follow-up, a total of 1 8  ( 1 5%) patients died and 30 (25%) patients were hospitalized for heart failure, significantly more often in non-responders (Table 4A) and patients with new-onset AF during follow-up (Table 4B). Table 4A. Clinical outcome: responders versus non-responders. 
Total popuLuion Responder Non-responder P-v,1lue All cause mortality, No. (%) CV mortality, No. (%) Progression of HF, No. (%) Sudden cardiac death Heart transplantation Time to CV mortality (months) Hospitalization for HF, No. (%) Time to Hospitalization (months) CV = cardiovascular; HF = heart failure. (n-= 1 20) (n=77) (n=43) 1 8  ( 1 5) 1 1  (9) 8 (7) 2 (2) 1 ( 1 )  20 ( 10-55) 30 (25) 8 ( 1 -5 1 )  6 (8) 2 (3) 2 (3) 0 0 1 5  ( 12- 1 9) 9 ( 12) 8 ( 1 - 1 5) 1 2  (28) 9 (2 1 )  6 ( 14) 2 (5) 1 (2) 20 ( 1 0-55) 21 (49) 8 ( 1 -5 1 ) Table 4B. Clinical outcome: new-onset AF versus permanent sinus rhythm 0.001 0.001 0.35 <0.000 1 0.28 
Total popuLnion New-onset AF  Pernunenr SR  P-Y,1 lue All cause mortality, No. (%) CV mortality, No. (%) Progression of HF, No. (%) Sudden cardiac death Heart transplantation Time to CV mortality (months) Hospitalization for HF, No. (%) Time to Hospitalization (months) (n= 1 20) (n= 1 7) (n= 1 03) 1 8  ( 1 5) 1 1  (9) 8 (7) 2 (2) 1 ( 1 )  20  ( 1 0-55) 30 (25) 8 ( 1 -5 1 )  5 (29) 3 ( 1 8) 2 ( 1 2) 1 (6) 0 1 2  ( 1 0-23) 9 (53) 7 (3-24) 13 ( 1 3) 8 (8) 6 (6) 1 ( 1 )  1 ( I )  1 8  ( 1 0-55) 2 1  (2 1 )  8 ( 1 -5 1 )  AF = atrial fibrillation; CV = cardiovascular; HF = heart failure; SR = sinus rhythm Predictors for response to CRT. 0.05 0 . 1 9  0.40 0.004 0.74 Multivariate analysis revealed that permanent sinus rhythm during follow-up (OR 8 . 1 [ 1 .4-29.7] , p=0.02), non-ischemic cardiomyopathy (OR 5 . 1 [ I .5- 16.9] , p=0 .008), a septal to lateral delay > 60 ms (OR 8 . 1 [2.8-13 .6] , p<0.000 1 )  and a higher systolic blood pressure (OR 4. 1 [ 1 .3-13 . 1 ] , p=0.02) were related to response (Table 5). Predictors for outcome. Predictors for more hospitalizations for heart failure or all-cause mortality were a larger left atrium (HR 3.3 [ I .6-6.8] , p=0.00 1 ) , a thinner left ventricular posterior wall (HR 4.5 [2.2-9.0] , p<0.000 1 ), and ischemic cardiomyopathy (HR 1 .8 [ I .0-3.8] ,  p=0.05), but not new-onset AF. 73 
Chapter 3 Table 5 .  Multivariate analyses of the total population - predictors for response to CRT Permanent sinus rhythm Non ischemic cardiomyopathy Sepral to lateral delay > 60ms Systolic blood pressure > 119  mmHg LV lead posterior LA, atrial length < 65 mm No previous myocardial infarction Univariate Analyses Multivariate Analyses OR (95% Cl) P value OR (95% CI) P value 5 .6 (1 .8-17.2) 2.8 (1 .3-6.1 ) 6.7 (2.7- 1 6 .5) 2.1 (1 .0-4.6) 2.3 (1 .0-5 .5)  2.3 (1 .1-5 .1) 2.2 (1 .0-4.7) 0 .003 0.01 <0.0001 0.06 0.05 0.04 0.05 8.1 (1 .4-29.7) 5 . 1  (1 .5-16.9) 8 . 1  (2.8-13.6) 4.1 (1 .3-13.1) 0.02 0.008 <0.0001 0.02 AF = atrial fibrillation, LA = left atrial, LV = left ventricular DISCUSSION. This study shows that new-onset AF occurs in 14% of the CRT patients and is prevented by successful CRT. Importantly, if new-onset AF occurs, it is associated with failure of CRT. Prognosis, however, is not worsened by AF, but by more severe underlying disease and non­response to CRT. Prevalence of new-onset AF in CRT patients. In heart failure patients, the occurrence of co-existent AF is strongly related to the underlying functional class. The incidence of AF increases with severity of heart failure and varies between 5 and 30%, with a yearly incidence of AF of 2-5%. 1 • 4-6• 20 Data on the prevalence of new-onset AF in CRT-D patients are scarce. In our study, 14% of patients developed new- onset AF during a mean follow-up of26 months. In a post-hoc analysis of the CARE-H F, H oppe et al. reported the occurrence of AF in 16% of the patients who received CRT during a follow-up of 29 months. In their study, however, AF was only documented by electrocardiograms, and in contrast to our study, not by the device.2 1 Furthermore, 19% of the patients in their study had a history of AF. A recent study from the group of Bax et al. reports a prevalence of new-onset AF in 25% of their CRT-D patients during a follow-up of 32 months.9 These figures are more or less comparable to ours and indicate the significance of new-onset AF during follow-up. Due to the device technology we could show the exact time of start of AF and outcome of a rhythm control strategy. In general, AF occurred after 1 year of CRT. Especially in non­responders AF occurred earlier during follow-up. Interestingly, short lasting episodes happened frequently, even in non-responders of CRT. 74 
New-onset AF and CRT New-onset AF and response to CRT. The present study shows that successful CRT is associated with a reduction in the occurrence of new-onset AF. The group of patients who responded to CRT showed, concomitantly with a reduction of LVESV and increase of LVEF, a significantly lower prevalence of new-onset AF. This reduction probably relates to improvement in cardiac function occurring in responders to CRT. Additionally, the reduction in atrial volume, occurring in harmony with a decrease of left ventricular end systolic volume, may play a role. Previously, Fung et al. compared 36 CRT patients without prior documented AF with a matched heart failure control group not treated with CRT.22 They observed a lower incidence of AF in the CRT treated patients (8% versus 3 1  %). Others demonstrated a reduction but no abolishment of AF during short term follow-up.23 In 84 patients, of whom 33 (39%) patients had previous documented AF, CRT reduced AF burden from 10 hours to 4 hours per day. In that study, no association with response to CRT, though, was made. A post-hoc analysis from the CARE-HF study reported no significant difference in AF between patients treated with CRT versus those with optimal medical therapy ( 16% versus 14%).2 1  However, when in the CRT group AF detected by the device was also taken into account, the percentage of patients with AF was significantly higher, being 39%. Also these investigators did not investigate the role of successful CRT on the occurrence of AF. In this respect, it is important to mention that differences in prevalence of AF during follow-up may relate to diverse detection modes (by ECGs alone or also by the device, including asymptomatic AF as well) and differences in patient groups. For example, patients known with AF are more prone to develop AF during follow-up.21 • 23• 24 To effectively assess the prevalence of AF, registrations of devices should be considered as also asymptomatic short lasting AF episodes may influence prognosis,25 and effectiveness of CRT due to high intrinsic ventricular rate response during AF, precluding effective biventricular pacing.26 Despite the severity of heart failure, rhythm control was effective in the majority of our patients. The latter may relate to the fact that in these patients rhythm control therapy could be initiated early after start of AF. Control of the device every 3-6 months revealed AF earlier during the course of the disease. Usually patients visit the outpatient clinic less frequently. Alternatively, optimal heart failure therapy including CRT in combination with antiarrhythmic drugs may have contributed to the excellent outcome of rhythm control therapy in the present patient group. Influence of new-onset AF on success of CRT and prognosis. Large trials have demonstrated the beneficial effect of CRT on clinical and echocardiographic parameters in sinus rhythm27• 28 and AF patients.9• 21 • 29 The present study shows that new-onset AF may impair response to CRT. The independent impact of AF on cardiovascular morbidity and mortality in the setting of heart failure is still controversial.4•8• 20• 30• 3 1 Most evidence suggests, however, that new-onset AF deteriorates prognosis in heart failure. 1 , 7• 8• 30 Our study shows that 75 
Chapter 3 new-onset AF is associated with a reduced success rate of CRT, but did not independently worsen hospitalizations for heart failure and all-cause mortality. This finding suggests that not AF but the underlying disease determines prognosis. 32 The latter is in line with the concept that AF is a marker of more severe disease in stead of that AF itself worsens prognosis. Corresponding to these thoughts, rhythm control was effective in the majority of our patients, i.e. most new­onset AF patients were predominantly in sinus rhythm during follow-up. Comparably, analysis of the CARE-HF, suggested that patients with AF during follow-up more frequently suffered from the primary endpoint (death or unplanned hospitalization), but also in that study this did not independently increase the risk.21  Others, however, demonstrated that during long term follow-up patients with new-onset AF showed a less favourable outcome, including more hospitalizations, appropriate and inappropriate shocks.9 Also in this study, though, survival was not significantly different between the two groups. Left atrial size and outcome. In responders, in line with a reduction of LVESV the left atrial volume significantly decreased during follow-up. This reduction in left atrial volume may have contributed to the prevention of AF. 33 In accordance, Fung et al. found that an improvement in the left atrial function during CRT (measured at 3 months follow-up) was associated with a reduction in the development of new-onset AF.34 Furthermore, we observed that a larger left atrial size predicted hospitalisations for heart failure and all-cause mortality. This points to the fact that left atrial size seems an important determinant of prognosis in heart failure.35•37 Limitations. The main limitation is the relatively small number of patients. This limits the power to adjust for multiple variables. Secondly, our analysis can not determine causality, whether new-onset AF post-CRT is a consequence or a cause of haemodynamic deterioration, i.e failure to CRT. However, all our data were gathered prospectively. Conclusion. Successful CRT reduces new-onset AF. New-onset AF is associated with failure of CRT but does not independently influence prognosis. Considering the above, AF merely seems a marker of severity of disease in stead of that AF itself worsens prognosis. 
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Importance of heart rate during exercise for response to cardiac resynchronization therapy 
Chapter 4 STRUCTURED ABSTRACT Background. Cardiac resynchronization therapy (CRT) is an established therapy for patients with severe heart failure and mechanical dyssynchrony. Response is only achieved in 60-70% of patients. Objectives. To study exercise-related factors predicting response to CRT. Methods. We retrospectively examined consecutive patients in whom a CRT device was implanted. All underwent cardiopulmonary exercise testing prior to implantation and after 6 months. The occurrence of chronotropic incompetence and heart rates exceeding the upper rate of the device thereby compromising biventricular stimulation was studied. Response was defined as a decrease in LVESV of 10% or more after 6 months. Results. We included 144 patients. After 6 months 86 (60%) patients were responders. Peak VO2 significantly increased in responders. Chronotropic incompetence was more frequently seen in non responders (2 1 (36%) versus 9 (10%), p=0.03), mostly in patients in SR. At moderate exercise, defined as 25% of the maximal exercise tolerance, i.e. comparable to daily life exercise, non-responders more frequently went above upper rate of the device ( 13 (22%) versus 2 (3%), p<0.0001) most of which were patients in permanent AF. Multivariate analysis revealed heart rates not exceeding the upper rate of the device during moderate exercise (OR 15.8 [3.3-76.5] , p=0.001) and non-ischemic cardiomyopathy (OR 2.4 [ l .0-5.7], p=0.04) as predictive for response. Conclusions. H eart rate exceeding the upper rate during moderate exercise is an independent predictor for non-response to CRT in patients with AF whereas chronotropic incompetence is a predictor for patients in SR. 
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CRT and exercise Cardiac resynchronization therapy (CRT) may improve symptoms, cardiac function, exercise capacity, peak oxygen consumption (peak VO2) ,  quality of life, and reduce mortality in patients with pharmacological refractory heart failure. J .7 The concept behind CRT is that cardiac contraction is resynchronized, thereby improving stroke volume, cardiac output and increasing the oxygen availability during cardiopulmonary exercise testing. H owever, response to CRT is only achieved in 60-70% of patients. 8· 9 Little attention has been paid to the importance of device programming with regard to heart rate during exercise in relation to response to CRT. H eart rates exceeding the preset upper (sensor) rate of the device, have been suggested as the cause for lower response to CRT in patients with atrial fibrillation (AF) . 1 0• 1 1  The role of exercise-induced loss of biventricular stimulation and chronotropic incompetence during exercise on the long-term clinical response to CRT has never been studied. The aim of the present study was to determine exercise-related factors for response to CRT. METHODS Patient population. Between January 2004 and January 2007, 144 consecutive patients with congestive heart failure who met eligibility criteria for CRT were included. The eligibility criteria for CRT were according to the guidelines: New York H eart Association (NYHA) functional class III or IV despite optimal pharmacological treatment, left ventricular ejection fraction $ 35%, a left ventricular end diastolic diameter (LVEDD) � 55 mm, and QRS duration � 130 ms. 12  Successful response to CRT was defined as a decrease in left ventricular end systolic volume (LVESV) of 10% or more measured by cardiac ultrasound after 6 months of follow-up.9 Baseline assessment included patient history, physical examination, 12 lead electrocardiogram (ECG), transthoracic echocardiography, treadmill cardiopulmonary exercise testing, radionuclide ejection fraction (EF) determination and coronary angiography. Mechanical dyssynchrony was determined by tissue velocity imaging, using Echopac 6. 1, General Electric Vingmed013 • Significant dyssynchrony was not a prerequisite for CRT implantation. We evaluated aortic pre­ejection time, interventricular mechanical delay (IVMD) and septal to lateral or septal to posterior delay. An IVMD>40ms was considered indicative of interventricular mechanical dyssynchrony. 1 3  lntraventricular LV dyssynchrony was measured by calculating the septal to lateral and posterior delay in peak velocities. 13 A mechanical delay >60ms was considered indicative of intraventricular dyssynchrony. 13 The pre-operative echocardiography was evaluated for akinetic areas and the maximal intraventricular delay to determine the optimal left ventricular lead position. Aerobic capacity (VO2 max) testing was performed according to a modified Bruce protocol. Peak VO2 (milliliters per minute) was measured as the highest average VO2 over 20 seconds as determined from two sequential IO-second periods at peak exercise. Peak VO2 (milliliters per 
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Chapter 4 minute per kilogram) was calculated as the dividend of peak VO2 and the patient's body weight. As the expected peak VO 2 is age and gender dependent, we used the percentage of the expected peak VO2 for analysis. The anaerobic threshold (AT, milliliters per minute) was measured by the V slope method, in which VCO2 is plotted against VO2 on X-Y coordinates of equal scale.14 AT is the VO2 where VCO2 increases faster then VO2, demonstrating that HCO3- is in the process of buffering lactic acid. AT was calculated as the peak VO2 at anaerobic threshold corrected for patient's baseline body weight. Heart rate response during exercise was investigated by assessing chronotropic response and the presence of continuous biventricular pacing. This was investigated after 6 months of follow up. Chronotropic incompetence was defined as failure to achieve > 70% of the age-predicted heart rate during exercise. The age-predicted heart rate was calculated as 220 - the patient's age. 15 The presence of continuous adequate biventricular pacing was investigated by examining electrocardiographic registrations during the total exercise test. Imperfect biventricular pacing during exercise was defined as heart rates exceeding the upper rate (maximum tracking rate) of the device at moderate exercise levels. Moderate exercise was defined as 25% of the maximal achieved exercise duration. This severity of exercise was chosen since these exercise levels correspond with exercise levels made by the patient during daily activities. At random patients received a Guidant'\ Medtronic" or Biotronik" ICD-CRT. The baseline peak VO2 (ml/min/kg) or echocardiographic parameters were not taken into account with regard to device selection. 
Follow up. All patients were seen at baseline and after 6 months of follow up at the outpatient department. At both visits, patient history, medication use, physical examination, ECG, pacemaker interrogation, a trans-thoracic echocardiography, a radionuclide scan and exercise test were performed. At each CRT interrogation, data was stored both on computer disc and in a computerized ICD medical record database of the University Medical Center Groningen. In most patients the device was programmed in the ODD mode (without rate response) with an optimized AV delay for the individual patient, a lower rate of 50/min and upper tracking rate of 130/min. In case of permanent AF devices were programmed in the VVI-R mode with an optimized VV delay for the individual patient, with a lower rate of 70 beats per minute (bpm); the upper sensor rate was usually programmed at 130 bpm. To ensure optimal biventricular pacing in AF patients, the ventricular sense response or biventricular trigger was activated in all AF patients. Cumulative percentages of ventricular pacing were recorded in the CRT device as the total number of ventricular paced beats in proportion to the total number of beats during follow up. Determination whether patient is a responder or non-responder was based on LVESV reduction measured by an independent examiner blinded for the clinical response of the patient at six months follow up. 84 
CRT and exercise Statistical analysis. Baseline descriptive statistics are presented as the mean ± standard deviation (SD) or median (range) for continuous variables and numbers with percentages for categorical variables. Differences between variables in patients in the responders versus those who did not respond were evaluated by Students t-test or Mann-Whitney U-test, depending on normality of the data, for continuous data, Fisher exact test or Chi-square test for categorical data. We calculated adjusted odds ratios of clinical characteristics, baseline drug therapy, and device characteristics with logistic regression , to identify predictors of CRT response. Linearity of the continuous variables with respect to the response variable was assessed by determining the quartiles of their distribution. Thereafter, odds ratios for each quartile were calculated. In case of a linear trend in the estimated odds ratios, the variable was introduced in the model as continuous. If no linearity was shown, the variable was further categorized by taking together the quartiles with odds ratios similar in magnitude, primarily the median value or otherwise based on clinical relevance. Multivariate analysis was performed using all variables with p <0. 1 0  in univariate analysis. A stepwise approach was used. The final model included all variables with p<0.05; variables with p�0.05 in the multivariate model were excluded. Interaction was investigated. In all analyses p<0.05 was considered statistically significant. RESULTS Patient characteristics. We included 1 44 patients. After 6 months of follow up 86 patients (60%) were responders. Baseline characteristics are shown in Table 1 .  Responders significantly more frequently suffered from non-ischemic cardiomyopathy (NICMP), had a septal-to-lateral delay > 60 ms, and more frequently had the left ventricular lead positioned in a posterior position (63 [73%] versus 3 1  [53%] , p=0.0 1 ). After 6 months of follow-up the percentage of biventricular pacing was similar between responders and non-responders (99 [60-1 00] % versus 98 [37-1 00] %, p=0. 1 8). 
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Chapter 4 Table 1 Baseline characteristics patients responders and non responders Total popuLuion Responder Non responder P-v,due Age (years) Male sex NYHA class III IV History of atrial fibrillation Atrial fibrillation at baseline Total duration AF (days) Duration current AF (days) Coronary Artery Disease Myocardial infarction Non ischemic cardiomyopathy Diabetes mellitus Hypertension Medication ACE/ARB B-Blokker Diuretics Digoxin Amiodarone Bloodpressure (mmHg) Systolic Diastolic eGFR (ml/min/1 .73 m2) Heart rate (bpm) QRS duration (ms) QRS > 1 50 QRS configuration LBBB RBBB Other LVEF Left atrial size, long axis (mm) LVEDD (mm) LVESD (mm) LVEDV (ml) LVESV (ml) Mitral valve regurgitation IV mechanical delay > 40 (ms) Septal to lateral delay >60 (ms) (n= 1 44) (n=86) ( 11=')8) 63 ± 11 63 ± 1 1  64 ± 1 1  1 09 (76%) 61 (71 %) 48 (83%) 133 (92%) 78 (91 %) 55 (95%) 11 (8%) 8 (9%) 3 (5%) 67 (47%) 42 (49%) 25 (43%) 28 ( 1 9%) 1 8  (21 %) 10 (17%) 1 ,457 (1 5-9,887) 1 ,531 (1 5-9,887) 1 ,124 (57-7,372) 392 (2-3,498) 359 (63-3,498) 581 (2-3,449) 65 (45%) 32 (37%) 35 (60%) 55 (38%) 26 (30%) 29 (50%) 79 (55%) 56 (65%) 23 (40%) 23 (16%) 8 (9%) 15 (26%) 49 (34%) 34 (40%) 15 (26%) 133 (92%) 83 (97%) 50 (86%) 1 11 (77%) 70 (81 %) 41 (71 %) 135 (94%) 82 (95%) 53 (91 %) 29 (20%) 16 (19%) 13 (22%) 39 (27%) 22 (26%) 17 (29%) 11 9 ± 19 121 ± 1 8  1 1 5 ± 20 71 ± 10  72 ± 10  71  ± 11  63 ± 21 65 ± 22 59 ± 20 72 (34-125) 69 (34-125) 75 (43-125) 166 ± 32 166 ± 31 168 ± 34 107 (74%) 63 (73%) 44 (76%) 94 (65%) 58 (67%) 36 (62%) 17 (12%) 6 (7%) 11 (1 9%) 33 (23%) 22 (26%) 11 (1 9%) 23 ± 8 23 ± 9 22 ± 7 49 (31-86) 48 (31-86) 51 (34-67) 68 ± 9 66 ± 9 70 ± 9 59 ± 9 57 ± 9 61 ± 9 230 ± 84 232 ± 92 226 ± 72 1 76 ± 71 1 81 ± 78 170 ± 61 30 (21 %) 20 (23%) 10 (17%) 30 (21 %) 18 (21 %) 12 (21%) 47 (33%) 33 (38%) 14 (24%) 0.48 0.11 0.45 0.50 0.65 0.72 0.96 0.003 0.02 0.003 0.008 0.09 0.20 0.13 0.33 0.58 0.62 0.10  0.49 0.12 0.11 0.69 0.73 0.03 0.36 O.Ql 0.009 0.03 0.69 0.39 0.28 0.12 0.04 ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; eGFR = estimated Glomerular filtration rate; IV = interventricular; LBBB = left bundle branch block; LVEF = Left ventricular ejection fraction; LVEDD = LV end diastolic diameter; LVEDV = LV end diastolic volume; LVESD = LV end systolic diameter; LVESV = LV end systolic volume; NYHA = New York Heart Association functional classification; RBBB = right bundle branch block. 86 
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Exercise related factors for response 
Chronotropic incompetence. 














20 Figure 1 Total group CI NHR AUR c::::J Responder c::::J non responder rr:::I] Responder, SR c:=:J Non responder, SR � Responder, AF � Non responder, AF Exercise related factors for response CI SR patients rnll ! !! !! · :· : •  Wil = : = : = 1 1 1 11 NHR AUR Cl AF patients NHR AUR Rare response during exercise rest for the total number of patients, patients with sinus rhythm and patients with atrial fibrillation. 
* P= <0.05 AUR = above upper rate during moderate exercise; CI = chronotropic incompetence; NHR = normal heart rate response 
Heart rate exceeding the upper rate of the device. Figure 2 shows an example of a patient who showed a heart rate above the tracking rate of the device at 25% of the exercise duration (heart rate 134 bpm) . After six months of follow up responders hardly ever exceeded the upper rate of the device during moderate exercise (2 of 86 (3%) versus 13 of 58 (22%), respectively, p <0.0001). (Table 2, figure 1). After 6 months of follow up patients who exceeded the sensor or tracking rate of the device during moderate exercise did not improve in peak V02 nor in % of expected peak V02 (from 13.7 [7.3-17.4] to 12.2 [9. 1-25.7] , p=0. 10, and from 54% ± 13 to 56% ± 20, p=0.58, respectively). Patients 
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CRT and exercise who did not exceed sensor or tracking rates showed a trend for an increase of peak VO 
2 and a significant increase in % of expected peak V02 (from 1 5. 1  [4.2-3 1 .5] to 16. 1  [8. 1 -35.4] , p = 0.07, and from 62% ± 21  to 66% ± 1 7 , p=0.005 , respectively). The influence of heart rate exceeding the upper rate of the device was restricted to patients with atrial fibrillation at the time of the exercise test (9 of the 28 patients (32%) with atrial fibrillation , versus 6 of the 1 16 patients (5%) with sinus rhythm, respectively, p<0.000 1 )  (Figure 1 ). The 9 AF patients all were a non responder (60%), 4 of the patients with sinus rhythm were a non responder ( 10%). (Figure I) Four of the 28 patients with AF had undergone AV node ablation after CRT implantation. There were no significant differences in upper rate programming between responders and non responders (128 ± 9 versus 126 ± 10 ,  p=0.23). The percentage of biventricular pacing recorded by the device was marginally lower in patients in whom the heart rate exceeded the sensor rate of the device during minimal exercise (99% [60- 100] versus 98% [37-1 00] , p=0.003). Predictors for heart rate exceeding the sensor rate of the device at moderate exercise were the presence of AF during follow up (OR 7.0 [ I .9-25.0] , p=0.003) and no beta blocker use (OR 8. 1 [2.3-29. 1 ] , p=0.00 1 ). The presence of ischemic vs. non-ischemic cardiomyopathy had no influence on heart rates. A 
9 1  
Chapter 4 B Figure 2 Electrocardiogram during exercise test of a patient that exceeds the upper rate of the device during moderate exercise 
Baseline electrocardiogram at the start of the exercise test (A) , and an example of heart rate exceeding 
the upper rate of the device at moderate exercise (heart rate 134 beats per minute). Note the absence of 







60 Figure 3 f f----1---.::i]* ---- . . ,,, . . ,,, . . f ,,,"" . . . . I . . . baseline • • • • • ]E"• . •· · · · · � • . . • ·  :.c...-----:::r: 25% 50% . . . . 75% __,.._ Chronotropic incompetent, mean heart rate • • • • • • Normal heart rate response, mean heart rate 1 00% Above upper rate during moderate exercise, mean heart rate Heart rate during exercise test CRT and exercise AUR responder n=2 AUR non responder n=l 3  NHR responder n=7 5 NHR non responder n=24 CI responder n=9 CI non responder n=2 l Heart rate response during exercise in patients with chronotropic incompetence, normal heart rate response and patients that exceed the upper rate of the device during moderate exercise. With the standard error of the mean. *P<0.05 
Predictors for response to CRT. Multivariate analysis revealed that predictors for response to CRT were non-ischemic cardiomyopathy (OR 2.4 [1.0-5.7] ,  p=0.04), and heart rate not exceeding the upper rate of the device at moderate exercise, being 25% of the maximal exercise (OR 15.8 [3.3-76.5] , p=0.001). 
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Chapter 4 DISCUSSION Our study shows that an exercise test may help to improve response to CRT. Chronotropic incompetence and heart rates above the sensor rate of the device during exercise were more frequently seen in non responders. Multivariate analysis revealed that heart rate exceeding the upper rate during moderate exercise is an independent predictor for non-response to CRT. Monitoring and adjustment of the device pacing features during exercise may therefore help to increase response to CRT. Exercise related factors for response - baseline exercise capacity. In our population, there was no difference in baseline VO 2max between responders and non­responders. This suggests that NYHA class is a less important factor than other predictors for response to CRT. Analysis by Bleeker et al. 16 found that patients with mild heart failure (NYHA II), showed a similar improvement in LVEF and amount of reverse remodeling with CRT as patients with NYHA III/IV. Exercise related factors for response - Chronotropic incompetence. The occurrence of chronotropic incompetence was significantly more frequently seen in non­responders. Chronotropic incompetence was only predictive in patients with sinus rhythm but not in patients with atrial fibrillation. No association could be found between the presence of chronotropic incompetence and the use of anti-arrhythmic drugs. In accordance with our findings, Tse et al. 1 5  observed in 20 patients treated with CRT that DDD pacing lead to chronotropic incompetence, defined as achieved heart rate corrected for age and gender, < 85% of expected. A total of 11 (55%) patients suffered from severe chronotropic incompetence, defined as achieved heart rate < 70% of expected. Patients with severe chronotropic incompetence significantly benefited from rate adaptive pacing (DDDR) with significant improvement of the exercise time, the reached amount ofMETs and peak VO2 during DDDR pacing in contrast to DDD pacing. In contrast to our study, they took an improvement in peak VO2 as their endpoint for response. On the other hand, atrial pacing may also have deleterious effects on outcome. 1 7 Bernheim et al. studied in 17 patients treated with CRT the acute hemodynamic effects assessed by Doppler echocardiography. Compared to atrial pacing (DDD), VDD pacing resulted in a much better improvement of intraventricular dyssynchrony, significantly prolonged the rate-corrected LV filling period and improved the myocardial performance index (calculated as the sum of the isovolumetric relaxation time and the isovolumetric contraction time divided by the ventricular ejection time). 16 Hereby, it should be noted that on top of the optimized AV delay in patient with DDD pacing a paced delay of 40 ms was programmed, which might have been to long for these patients. Obviously, this issue warrants further investigation, preferably in a randomized trial. 94 
CRT and exercise Exercise related factors for response - Heart rate exceeding the upper rate of the device. We observed that patients who do not exceed the upper rate of the device during moderate exercise (25% of the maximal achieved exercise capacity) more frequently responded to CRT. Patients exceeding the upper rate at moderate exercise probably also more frequently exceed the upper rate during their daily activities. This may compromise the beneficial effects of the implanted device. Therefore, in CRT patients we encourage close examination of exercise tests, and subsequently adequate reprogramming of the device if necessary, e.g. adding more negative chronotropic drugs or adjustment of the upper rate of the device. In accordance with other large randomized CRT trials, 3-7 only 77% of patients used beta blocker at the time of implantation. As the absence of beta blocker use was an independent predictor for heart rates exceeding the upper rate of the device, optimalization of beta blocker use or other negative chronotropic drugs, should be first choice therapy. Assessment if patients go above the upper rate of the device during exercise is difficult to determine by examining the amount of biventricular pacing as provided by the device. Fusion pacing is often counted as pacing and may interfere with the actual rate of effective biventricular pacing. Indeed, our results show that there was only a slight difference in the amount of biventricular pacing. This may relate to an overestimation of the true amount of biventricular pacing due to fusion pacing. Only during exercise tests loss of biventricular pacing may become apparent as it can be easily detected on the electrocardiograms. There are few studies done with regard to the impact of optimal programming of the CRT devices during exercise in patients with heart failure. 1 5 Previously, Auricchio et al.1 8  suggested that when determining the anaerobic threshold, careful attention should be paid to the heart rate with regard to the maximal tracking rate of the device. They found in their analysis of 50 patients treated with CRT that chronotropic incompetence during exercise tests prior to implantation was frequently reverted in patients treated with CRT, and that the loss of atrioventricular sequential pacing during exercise, and thus of biventricular pacing, was immediately followed by a reduction of peak V02• Another study has suggested that response is correlated with the amount of biventricular pacing1 1 • But no previous study highlighted the importance of heart rates exceeding the upper rate of the device during moderate exercise, i.e. resembling what happens during daily life. In line with previous data, we observed that patients with AF significantly more often exhibit heart rates above the sensor rate of the device during moderate exercise compared to patients in sinus rhythm. This implies that patients with AF should routinely undergo AV node ablation to achieve permanent pacing and thereby optimal cardiac resynchronization, unless heart control can be easily achieved. 1 1 • 19-21 We suggest, however, that in many patients with AF adequate heart rate control can be achieved with medication and that these patients have as good a chance to be responders as patients in sinus rhythm with normal heart rates. We suggest that attempts should 
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Chapter 4 first be made to optimize programming of the CRT device and use exercise tests to stratify which patients actually need AV node ablation. Furthermore it is important to check the device for occurrence of (paroxysmal) AF because we have previously demonstrated that new-onset AF is negatively correlated with CRT response. 22 Predictors for response. In the present study, we found that in addition to heart rates exceeding the upper rate of the device during moderate exercise that NICMP was predictive for response. This is in accordance with results found by others.7' 1 3, 23 Several studies have proven that patients with NICMP have a better probability of responding to CRT than those with ischemic cardiomyopathy.23, 24 Analysis revealed no association between the aetiology of heart failure and the occurrence of heart rates exceeding the upper rate of the device during moderate exercise, or chronotropic incompetence. Other frequently found predictors for response to CRT, being left ventricular lead position positioned posterior,25' 26 and the septa! to lateral delay 1 3' 27 were significantly more frequently seen in responders, univariately we also found these variables to be predictors for response to CRT, however they did not remain standing in the multivariate model. Limitations. This is an observational, retrospective analysis, and is affected by all limitations of these studies. On the other hand, because of a prospective real-time database implementation, we have minimal missing data, and all our patients are consecutive, which limits possible patient selection bias. A second limitation is that our results cannot prove causality of the relation between heart rates and response. Further prospective randomized studies have to demonstrate that interventions aimed at preventing heart rates exceeding device upper rates as well as increasing sensitivity of sensor programming to prevent chronotropic incompetence will actually improve outcome of CRT. Conclusion. As more patients with advanced heart failure are treated with CRT, the results of this study provide useful information regarding the optimal use of the device with regard to increasing the number of responders to CRT. Prospective studies are warranted. 96 
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The impact of interventricular lead distance and the decrease in septal to lateral delay on response to Cardiac Resynchronization Therapy 
Chapter 5 STRUCTURED ABSTRACT Objectives. To investigate the influence of interlead distance and lead positioning on success of cardiac resynchronization therapy (CRT) in patients with advanced chronic heart failure (CHF) and electrical dyssynchrony. Despite application of established selection criteria 20-40% of patients do not respond to CRT. Methods. We examined consecutive patients in whom CRT was implanted. Response to CRT was defined as a decrease in left ventricular end systolic volume � 10% after 6 months. A comparison of patients who were responders to CRT and patients who were non responder was made. An univariate and stepwise multivariate logistic regression with regard to predictors for response was done. Results. BetweenJanuary 2004 untilJanuary 2008, 174 patients who were treated with CRT were classified as responder (n=95, [55%])  or non responder (n=79, [45%]) .  Responders had significantly larger horizontal interlead distance on the lateral thoracic X-ray (OR 2.8 [ 1.2-6.6] , p=0.01), a septal 
to lateral delay >60 ms (OR 4.9 [2.0-11.4] p<0.0001), non ischemic cardiomyopathy (OR 3.0 [1.3-6.9], p=0.009), a left ventricular end diastolic diameter <67 mm (OR 4.2 [ 1.8-9.9] , p=0.001), ACE inhibitor use (OR 8. 1 [1.7-38.2] ,  p=0.008) and no tricuspid valve insufficiency (OR 6.9 [1.3-35 .5] , p=0.02) . Post implantation responders had a significantly greater decrease in intra-ventricular (septal to lateral delay 62±62 ms versus 26±65 ms, p=0.001) but not inter­ventricular mechanical delay. Conclusion. Larger interlead distance on the lateral thoracic X-ray, associated with positioning of the left ventricular lead in a posterior position is associated with response after 6 months of follow-up. Furthermore, diminishing the septal to lateral delay is predictive for response. 
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lnterlead distance and response to CRT Heart failure is the fastest growing cardiovascular diagnosis; the lifetime risk is estimated at nearly 20%. According to epidemiologic studies, an estimated 22.5 million people worldwide suffer from heart failure. 1 Intraventricular conduction disturbances are common and are associated with an increased mortality.2• 3 Several randomized clinical trials have demonstrated the beneficial effects of cardiac resynchronization therapy (CRT) in patients with pharmacological refractory heart failure.3-10  These studies have shown an improvement in clinical (symptoms, exercise capacity, quality of life, mortality) and echocardiographic end points (systolic function, left ventricular size, mitral valve regurgitation). However, depending on the criteria used for definition of response, 20-40% of the patients do not respond to CRT. At present the eligibility criteria for CRT are New York Health Association (NYHA) functional class III or IV despite optimal pharmacological treatment, left ventricular ejection fraction $ 35%, left ventricular end diastolic diameter (LVEDD) � 55 mm, wide QRS complex � 130 ms. 11 According to recent literature, evident dyssynchrony by echocardiography was taken into account in case of a QRS duration $ 130 ms. 12  Decrease in the left ventricular end systolic volume (LVESV) of more then 10% has been shown to be predictive for lower long term mortality and heart failure events. 1 2• 1 3  Positioning of the left ventricular lead is often difficult due to the characteristics of the coronary venous anatomy, unacceptable electrical parameters in the target area, phrenic nerve stimulation, and/ or other technical difficulties. The aim of the present study was to investigate the independent influence of interlead distance and thus lead position on response to CRT. METHODS Patient population. Between January 2004 and January 2008, 194 consecutive patients with congestive heart failure received CRT. Patients who died prior to 6 months follow up and thus did not have a follow-up cardiac ultrasound to determine changes in LVESV were left out of this analysis (n=20). Response was defined as a decrease of 10% or more in left ventricular end systolic volume (LVESV) after 6 months of follow up. A total of 95 (55%) patients were classified as responders, the remaining 79 (45%) patients were non-responders. Baseline assessment included patient history, physical examination, 12 lead-electrocardiogram (ECG), transthoracic echocardiography, exercise testing, radionuclide scanning and coronary angiography. Clinical history and characteristics were retrieved using patient medical records. QRS duration was determined using ECG stored in medical records. A transthoracic echocardiography was made to determine whether there were signs of tricuspidalis valve or mitral valve regurgitation, the severity of regurgitation was graded semi-quantitively from color 
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Chapter 5 flow Doppler in the parasternal long axis and apical 4-chamber images. Left ventricular end diastolic diameter (LVEDD) and systolic diameter (LVESD) were determined by M-mode echocardiography in the parasternal long axis view according to the guidelines of the American Society of Echocardiography. 14 Left ventricular end diastolic volumes (LVEDV) and end systolic volumes (LVESV) were measured using the modified biplane Simpson method using the apical four-chamber and two-chamber views. 1 5 Mechanical dyssynchrony was determined by tissue velocity imaging (TVI), using Echopac 6. 1.3, General Electric Vivid 7'. We evaluated the aortic pre-ejection time, interventricular mechanical delay (IVMD) and septal to lateral delay by TVI. An IVMD>40ms was considered indicative of interventricular mechanical dyssynchrony. 1 2  lntraventricular LV dyssynchrony was measured by calculating the septal to lateral delay. A mechanical delay >60ms was considered indicative of intraventricular dyssynchrony. 1 2  Right and left ventricular lead positioning were determined by chest X-rays in postero-anterior and lateral views, at maximal inspiration, typically on the day after device placement. The LV lead tip position was defined as posterior (within the posterior 1 /3 of the heart shadow on the lateral radiograph), all other positions were defined as other. The interlead-distance is measured on a digital radiology workstation, whereby the thoracic width, the cardiac width, the direct RV-LV electrode tip separation, the horizontal and vertical components of LV-RV electrode tip separation were measured. (Figure I )  All measurements were divided by the cardiothoracic ratio to account for relative differences in cardiac and thoracic size between patients, creating the corrected interlead distance. 
A B 
LJ V 
H Figure 1 1 04 
Interlead distance and response to CRT Measurement of the RV-LY interlead distance in anteroposterior position (panel A) and lateral (panel B) Interlead distance measured as direct (D), horizontal (H) , and vertical (V) on each radiograph. 
Follow up. Post implantation all patients underwent echocardiography to determine the persistence of IVMD and/or septal to lateral delay. Thereafter all patients were routinely seen every 6 months at the out patient department. At all visits, patient history, medication use, physical examination, ECG, pacemaker interrogation, transthoracic echocardiography, a radionuclide scan, and exercise test were performed. At each CRT interrogation, data was stored both on computer disc and in a computerized ICD medical record database of the University Medical Center Groningen. A consistent protocol to standardize CRT and ICD programming was used. W delay was set to 0 ms, AV delay optimization was performed 2 weeks post implantation. Duration of follow up was computed from the time of CRT implantation until death or heart transplantation when applicable, or to the date when the last follow up data were obtained. Determination whether patient was a responder or non-responder was based on the LVESV measured by echocardiographic ultrasound at six months follow-up. 
Statistical analysis. Baseline descriptive statistics are presented as the mean ± standard deviation (SD) or median (range) for continuous variables and numbers with percentages for categorical variables. Differences between variables in patients in the responders versus those that did not respond were evaluated by Students t-test or Mann-Whitney U-test, depending on normality of the data, for continuous data, Fisher exact test or Chi-square test for categorical data. We calculated adjusted odds ratios of clinical characteristics, baseline drug therapy, and device characteristics with logistic regression, to identify predictors of CRT response. Linearity of the continuous variables with respect to the response variable was assessed by determining the quartiles of their distribution. Thereafter, odds ratios for each quartile were calculated. In case of a linear trend in the estimated odds ratios, the variable was introduced in the model as continuous. If no linearity was shown, the variable was further categorized by taking together the quartiles with odds ratios similar in magnitude, primarily the median value or otherwise based on clinical relevance. Multivariate analysis was performed using all variables with p<0. 10 in univariate analysis. A stepwise approach was used. The final model included all variables with p<0.05; variables with p�0.05 in the multivariate model were excluded. Interaction was investigated. In all analysis p<0.05 was considered statistically significant. 1 05 
Chapter 5 RESULTS Patient characteristics. We included 174 patients of whom 95 (55%) patients were responders to CRT after 6 months of follow-up. The baseline characteristics are shown in Table 1. Responders significantly more frequently suffered from non ischemic cardiomyopathy (NICMP), more frequently had a IVMD >40 ms, a septal to lateral delay >60 ms, smaller left atrium, smaller left ventricular diameters and volumes, and had a higher estimated Glomerular filtration rate. Analysis of the thoracic X-rays proved that the right ventricular lead most frequently was placed in the apex and the left ventricular lead in a posterior position. Responders significantly had larger corrected horizontal interlead LV-RV distance, on the lateral X-ray. (Table 2) This coincided with the left ventricular lead more frequently being positioned in a posterior position. (figure 2) 
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Interlead distance and response to CRT Tabel 1 Baseline characteristics responders versus non responders Age (years) Male sex History of AF AF baseline NYHA class III IV Coronary Artery Disease Previous MI Non Ischemic Cardiomyopathy DM Hypertension Systolic blood pressure Diastolic blood pressure eGFR (ml/min/1 .73 m2) QRS duration (ms) QRS > 1 50 QRS configuration LBBB RBBB Other LVEF Left atrial, long axis (mm) LVEDD (mm) LVESD (mm) LVEDV (ml) LVESV (ml) RV-TAPSE (mm) MV regurgitation (#) TI regurgitation (#) QRS AV opening (ms) QRS PV opening (ms) IVMD (ms) IVMD > 40 ms SL delay (ms) SL > 60 ms Medication ACE/ARB �-Blocker Diuretics Digoxin Tora! popuLuion Responder Non responder P-v,1 luc (n-= 1 74) (n=9':i) (n=79) 63 ± 11 127 (73%) 78 (45%) 35 (20%) 1 61 (93%) 13 (7%) 79 (45%) 68 (39%) 96 (55%) 29 (17%) 62 (36%) 1 1 8  ± 1 8  7 2  ± 1 0  64 ± 21 166 ± 31 1 31 (75%) 1 1 8  (68%) 19 (10%) 37 (22%) 23 ± 8 49 (30-86) 67 ± 9 58 ± 9 249 ± 94 1 97 ± 83 1 7  ± 5 39 (22%) 13 (7%) 1 62 ± 39 127 ± 26 33 ± 41 62 (36%) 63 ± 52 91 (52%) 1 59 (91 %) 143 (82%) 162 (93%) 34 (20%) 62 ± 12  67  (71%) 42 (46%) 20 (21 %) 88 (93%) 7 (7%) 31 (33%) 26 (27%) 64 (67%) 8 (8%) 39 (41 %) 121 ± 1 8  72 ± 9 67 ± 22 1 66 ± 31 69 (73%) 70 (74%) 6 (6%) 1 9  (20%) 24 ± 9 48 (30-86) 66 ± 9 57 ± 9 230 ± 64 1 80 ± 52 18 ± 5 22 (23%) 3 (3%) 1 68 ± 40 127 ± 25 41 ± 42 38 (40%) 77 ± 55  61  (64%) 92 (97%) 82 (86%) 90 (95%) 16 (17%) 65 ± 1 0  6 0  (76%) 36 (46%) 1 5  (1 9%) 73 (92%) 6 (8%) 48 (61 %) 42 (53%) 31 (39%) 21 (27%) 23 (29%) 1 1 5  ± 1 8  7 0  ± 1 1  5 9  ± 20 1 66 ± 30 62 (78%) 48 (61%) 1 3  (16%) 1 8  (23%) 23 ± 7 50 (31-67) 68 ± 9 60 ± 9 264 ± 111  210 ± 99 1 7 ± 5  17  (22%) 10 (13%) 1 55 ± 36 128 ± 28 25 ± 38 24 (30%) 47 ± 43 30 (38%) 67 (85%) 61 (77%) 72 (91 %) 18 (23%) 0.1 9 0.42 0.86 0.91 0 .34 <0.0001 0.001 <0.0001 0.001 0.1 0 0 .03 0.1 9 0.005 0.99 0.37 0.07 0.41 0.12 0.04 0.03 0.03 0.03 0.60 0.63 0.03 0.06 0.74 0. 03 0.03 <0.0001 <0.0001 0.005 0.12 0.35 0.33 ACE = angiotensine converting enzyme; AF = atrial fibrillation; ARB = angiotensine receptor blocker; AV = aortic valve; DM = diabetes mellitus; eGFR = estimated Glomerular filtration rate; LBBB = left bundle branch block; LVEDD = left ventricular end diastolic diameter; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; LVESV = left ventricular end systolic volume; IVMD = inter ventricular mechanical delay; MI = myocardial infarction; MV = mitral valve; NYHA = New York Health Association; PV = pulmonary valve; RBBB = right bundle branch block; RV = right ventricle; SL = septal to lateral; TV = tricuspidalis valve # = moderate or severe 1 07 
Chapter 5 Table 2. Lead positioning Total populat ion Responder Non responder P-value Localization LV lead Posterior Other Localization RV lead Apex RVOT Measurements X-ray CTR lnterlead distance/CTR H-frontal X-ray (mm) V- frontal X-ray (mm) D-frontal X-ray (mm) H-lateral X-ray (mm) V-lateral X-ray (mm) D-lateral X-ray (mm) ( n- 1 74) (n=95) (n=79) 1 22 (70%) 73 (77%) 49 (62%) 49 (28%) 2 1  (22%) 28 (35%) 1 59 (9 1 %) 91 (96%) 68 (86%) 1 1  (6%) 2 (2%) 9 ( I  1 %) 0.56 ± 0.07 0.55 ± 0.06 0 .57 ± 0.07 48 ± 32 50 ± 33 45 ± 32 82 ± 45 83 ± 42 8 1  ± 49 1 02 ± 40 1 03 ± 38 1 0 1  ± 41  1 27 ± 64 1 39 ± 62 1 1 2 ± 65 81 ± 45 8 1  ± 42 8 1  ± 48 16 1  ± 52 1 70 ± 5 1  1 5 1  ± 52 0.0 1 0.0 1 0 .02 0.29 0.87 0.75 0 .007 0.99 0.02 CTR = cardiothoracic ratio; D = direct interlead distance; H = horizontal; LV = left ventricular lead; RV = right ventricular; RVOT = right ventricular outflow tract; V = vertical. 
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Chapter 5 Dyssynchrony after implantation. The septa! to lateral delay was significantly more reduced in responders after implantation ( 62±62 versus 26±65, p=0.001). (Figure 4) Responders significantly less frequently had a septa! to lateral delay >60 ms after implantation of the CRT device ( 11 [12%] versus 28 [35%] , p=< 0.0001). There was no significant difference in the decrease of interventricular mechanical delay between both groups ( 14±38 versus 13±39, p=0.39). Evaluation oflead positioning showed that the septa! to lateral delay significantly more diminishes in patients whereby the left ventricular lead is positioned posterior. (Figure 3) Response to therapy. Median follow-up was 21±12 months. After 6 months of follow up 95 (55%) patients were defined as responders. The LVESV had decreased significantly in responders, whereas non­responders showed a significant increase in LVESV (Figure 4A). The LVEF increased significantly in responders, in the non-responders the LVEF decreased slightly (Figure 4B). After 6 months of follow up 128 patients were responders by decrease oh I NYHA class. Of the echocardiographic responders 73 (78%) patients were NYHA responders whereas the remaining 21 (22%) echocardiographic responders did not improve in NYHA class. Of the echocardiographic non­responders 55 (70%) patients improved one or more points in NYHA class. Multivariate analysis revealed that a horizontal interlead distance on the lateral X-ray >127 mm (OR 2.8 [ I .2-6.6] , p=0.01), a septa! to lateral delay >60 ms (OR 4.9 [2.0-11.4] , p<0.0001), NICMP (OR 3.0 [1.3-6.9], p=0.009), LVEDD < 67 mm (OR 4.2 [1.8-9.9] , p=0.001), ace inhibitor use (OR 8. 1 [ I .7-38.2] ,  p=0.008) and no tricuspid valve regurgitation (OR 6.9 [ 1.3-35.5], p=0.02) were related to response (Table 3). Tabel 3 .  Univariate en stepwise multivariate logistic regression analyses with regard to predictor responder. Variable Univariate analysis Multivariate analysis * H-lateral X-ray > 1 27mm SL-delay > 60 ms NICMP LVEDD < 67 mm ACE-inhibitor No TV regurgitation Odds ratio (95% Cl) P-value Odds ratio (95% CI) P-value 2.6 (1 .4-5.8) 0.003 2.8 ( 1 .2-6.6) 0.01 4.0 (2.0-8.0) <0.0001 4.9 (2.0-11 .4) <0.0001 3.0 (1 .6-5 .6) <0.0001 3.0 (1 .3-6.9) 0.009 2.4 (1 .3-4.4) 0.006 4.2 (1 .8-9.9) 0.001 5.5 (1 .5-20.2) 0.01 8.1 (1 .7-38.2) 0.008 4.2 (1 .1-1 5 .7) 0.04 6.9 (1 .3-35 .5) 0.02 * There is no significant interaction between parameters in the end model. ACE = angiotensine converting enzyme; H = horizontal; LVEDD = left ventricular end diastolic diameter; NICMP = non ischemic cardiomyopathy; SL = septa! to lateral; TV =  tricuspid valve 110  
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Chapter 5 DISCUSSION This study demonstrates that the interlead distance, in particular the horizontal interlead distance on the lateral thoracic X-ray is associated with response to CRT after 6 months of follow-up. The horizontal interlead distance correlated best with a posterior positioning of the left ventricular lead. None of the other interlead distances were of influence on response. This suggests that the currently desired lateral placement of the LV lead is of less importance for response to CRT. Furthermore, response to CRT was associated with the diminishing of the septal to lateral delay during follow up. This reduction of the septal to lateral delay was significantly more when the left ventricular lead was positioned in a posterior position. This strengthens the body of evidence that relieving mechanical dyssynchrony is the basis for efficacy of biventricular stimulation. Response to CRT. In the present study 55% of patients were responders to CRT, defined as a decrease in LVESV of 10% or more. This is in accordance with results found by Yu et al. 13 Response rate was significantly higher when an improvement of � 1 NYHA class was evaluated. In accordance with our data, other studies found a poor relation between clinical response and echocardiographic response to CRT. 1 6  Influence of lead positioning. In our analysis a larger horizontal interlead distance on the lateral thoracic X-ray correlated with response. This coincided with a posterior positioning of the LV lead and offers an advantage over other lead positions. By changing the current fluoroscopic views used for implantation of the left ventricular lead left anteriour oblique (LAO) 30-40° to a fluoroscopic view LAO 90°, frequently used in coronary angiography, the best posterior vein can be selected. Hereby it should be taken into account that the choice of left ventricular electrode site for best resynchronization is often difficult because of the characteristics of the coronary venous anatomy, unacceptable electrical parameters in the target area, phrenic nerve stimulation, or other technical difficulties. Earlier studies have shown the lateral or posterolateral part of the left ventricle as the site that provides greatest acute hemodynamic benefit, particularly for dp/dt, 17•20 Butter et al. found that the acute hemodynamic effects were significantly better when the LV lead was positioned in the free wall compared with an anterior positioning of the LV lead. 19 Along the same lines, Rossillo et al. showed that positioning of the left ventricular lead in the lateral and posterolateral coronary veins was associated with significant improvement in functional capacity and greater improvement in left ventricular function compared with the anterior coronary vein locations.2 1  Heist et al.20 analyzed the effect of a larger horizontal inter-lead distance, whereby especially the interlead distance on the lateral X-ray influenced acute hemodynamics. No information, however, over 
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Interlead distance and response to CRT objective long-term response is available. We could now demonstrate that this simple parameter can be used to predict response to biventricular stimulation. The vertical interlead difference between RV and LV lead, neither frontal or lateral X-ray, was not of influence with regard to response rate. This coincides with acute hemodynamic results found by Gold et al. 22 Bax et al. 23• 24 were the first to determine that diminishing of the septal to lateral delay by biventricular pacing was associated with response to CRT. In analogy with our results they found that the septal to lateral delay significantly decreased with CRT. In contrast to our results Gasparini et al., could not find a significant difference in lead positioning and amount of clinical responders.25 It should be noted, however, that they found a significant correlation with increase in LVEF which in several studies 1 3  was correlated with left ventricular remodeling and patient outcome (in contrast with clinical parameters). Influence of RV lead localization. In our population non responders more frequently had the right ventricular lead localized in the right ventricular outflow tract (RVOT), this observation is in accordance with results found by Van Gelder et al, who found in 82 patients a significant difference in LV dP/dt max between patients with biventricular pacing with placement of the right ventricular lead in the apex being superior to placement in the septal wall, hereby it should be taken into account that this difference disappeared after V-V optimalization. 26 Possibly a larger interlead separation is created by placement of the RV lead in the apex. 20 Dyssynchrony after implantation. Responders had a significantly larger decrease in intra-ventricular mechanical delay after implantation of the CRT. Even so, positioning of the left ventricular lead in a posterior position led to a greater decrease of the septal to lateral delay. The finding that the intra-ventricular mechanical delay decreases in responders in contrast to the non responders is in accordance with results found by others.23• 24 The fact, however, that positioning of the left ventricular lead in a posterior position more frequently was associated with a decrease of intra-ventricular mechanical delay has never previously been described before. Predictors for response. In the present study we found that predictors for response were in addition to a larger horizontal inter-lead distance on the lateral thoracic X-ray: a septal to lateral delay > 60 ms, NICMP, a smaller LVEDD, the use of an ACE inhibitor and no tricuspid valve regurgitation. These results are in accordance with results found by others. 10• 1 2• 27 Several studies have proven that patients with NICMP have a better chance for response to CRT than patients with ischemic cardiomyopathy.28-3 1  Sogaard et al. 28, found a difference in contraction delay between ischemic and non ischemic patients with the greatest contraction delay in the lateral and posterior LV 1 1 3 
Chapter 5 walls for NICMP and in the septum and inferior walls for those with ischemic cardiomyopathy28• Possibly this difference in conduction delay could explain the influence of lead positioning. Further studies have shown that positioning of the left ventricular lead in previous scar tissue is associated with non response.29• 30 In accordance with our results Richardson et al.27 found that patients with non-ischemic cardiomyopathy responded more frequently to CRT. Bax et al. 1 2  found that a septal to lateral delay of >60 ms is predictive for response to CRT, we could confirm this in our study. Limitations. The main limitation is the relatively small number of patients, partly due to missing data due to relocation of patients or death prior to the six months follow up and therefore left out of analysis. This limits the power to adjust for multiple variables. Furthermore, patients who died prior to the six months follow up were left out of analysis. Conclusion. The present study highlights that lead positioning is predictive for response to CRT. Larger interlead distance on the lateral thoracic X-ray, associated with positioning of the left ventricular lead in a posterior position, is associated with response after 6 months of follow-up. Furthermore, diminishing the septa! to lateral delay is predictive for response. 114 
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How to prevent ICD shocks 
Chapter 6 A 63-years old male with a non ischemic cardiomyopathy due to a hereditary autosomal dominant desmin mutation (left ventricular ejection fraction 30%), and a history of persistent atrial fibrillation and flutter since 1990 received in December 2006 an implantable cardioverter defibrillator (ICD, Medtronic® Virtuoso DDD ICD). He was known with a first degree atrioventricular block, intermittent 2nd degree atrioventricular block, Mobitz type I, during low dose sotalol (40 mg twice daily). In September 2007, he visited our outpatient ICD clinic because of 2 shocks (Figure 1). He complained of a small decrease in exercise tolerance. Physical examination revealed basal pulmonary rales. Figure 2 shows the Cardiac Compass Trends. At the time of the shocks he was treated with enalapril 10 mg twice daily, bumetanide 1 mg daily, sotalol 40 mg twice daily, and acenocoumarol. His pacing mode was DD D lower rate 40 bpm, upper rate 130 bpm. Detection border for atrial arrhythmias started above 171 bpm, without therapies. Detection and therapies for ventricular arrhythmias started above 200 bpm. Therapies for ventricular arrhythmias included antitachycardia pacing during discharge, and 5 shocks thereafter (1st shock 25 Joules, 2nd, 3rd, 4th and s ch shock 35 Joules). Analysis of the ICD after the shocks showed a normal impedance of the atrial (368 ohms) and RV lead (536 ohms), the amount of ventricular pacing was 28%. 
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How to prevent ICD shocks Part I 
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Questions: 1. Were there adequate shocks? Was the first shock effective? What happened before the first shock? 2. What was the aerial rhythm before and after the first shock? 3. How to interpret the cardiac compass trend? 4. How can we possibly prevent (part of the) shocks in the future? 
Answer to questions: Patient developed persistent atrial fl.utter in June 2007 (Figure 2 and 3A, cycle length 230 msec). The mean ventricular rate during atrial flutter was high (mean cycle length < 500 msec, i.e. > 120 bpm). The day of presentation patient developed a fast ventricular tachycardia (VT, cycle length 280 msec, Figure 3B). The ventricular tachycardia was treated first with a burst (cycle length 250 msec) during charging (Figure 3B), which was unsuccessful (Figure 3C). The first shock (25,4 Joules) was delivered somewhat later and cardioverted aerial flutter into aerial fibrillation (Figure 3D). The ventricular tachycardia, however, persisted (Figure 3C and D). The second shock (34,6 Joules) eventually stopped the ventricular tachycardia (3 E and F). 1 2 1  
Chapter 6 As is demonstrated in Figure 2, atrial flutter was continuously present since June 2007 and had induced a rise in the OptiVol index, while there was a steady line of decrease of the thoracic impedance since the beginning of June 2007 (Figure 4). This may indicate an increase in pulmonary fluid congestion, which was supported by the results of physical examination. Furthermore, analysis of the patient activity (Figure 2), also indicates a small decrease in activity the six weeks prior to the appropriate ICD shocks. Analysis of the cardiac compass proves that more then 10 weeks prior to the appropriate ICD shock the OptiVol fluid index had been steadily increasing, indicating a possible fluid accumulation. Probably, this fluid index increase relates to the development of heart failure triggered by the start of persistent atrial flutter with a high ventricular rate, which eventually elicited the ventricular tachycardia. The association between atrial flutter/ fibrillation, heart failure and appropriate shocks because of ventricular tachycardia has been described before. 1 -3 This case illustrates that due to ongoing atrial flutter with an irregular heart rate almost continuously above 100 bpm (Figure 3A) the patient developed slowly progressive heart failure, ultimately leading to the ventricular tachycardia. Possibly, the use of home monitoring or the use of OptiVol fluid alarm, might have prevented the occurrence of the ventricular tachycardia and thus 2 shocks in this patient. Early detection of an increase of fluid retention and the development of atrial flutter/ fibrillation, would have made an early intervention possible in order to treat heart failure. Several studies have proven that persistent AF and new onset AF are associated with more appropriate ICD shocks and hospitalizations for heart failure. 1 -3 There are several theories, with regard to the association between AF and appropriate ICD shocks. A possible cause can be hemodynamic deterioration, as was the case in the present patient. Furthermore, high heart rates may induce ischemia leading to ventricular arrhythmias, and last but not least, the irregularity of AF leading to short-long-short sequences may be intrinsically pro-arrhythmic. Currently studies are being performed with home monitoring to determine whether the amount of hospitalizations for heart failure and/ or shocks can be decreased. A retrospective interim analysis by Ellery et al. suggested a correlation between data found by home monitoring and hospitalization. 4 122 
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How to prevent ICD shocks Part I 
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OptiVol fluid index is an accumulation of the difference between the daily and reference impedance. Figure 4 OptiVol fluid index Conclusion We report a patient with appropriate ICD shocks, in whom in retrospect the ventricular tachycardia probably was triggered by progression of the heart failure due to persistent atrial flutter with a high ventricular rate. With home monitoring or the use of the OptiVol alarm the ICD shocks possibly could have been prevented by earlier intervention. 1 25 
Chapter 6 REFERENCE LIST 1 26 ( 1 )  Zareba W, Steinberg JS ,  McNitt S, Daubert JP, Piotrowicz K ,  Moss AJ . Implantable cardioverter­defibrillator therapy and risk of congestive heart failure or death in MAD IT II patients with atrial fibrillation. Heart Rhythm 2006;3:63 l-7. (2) Singh JP, Hall WJ, McNitt S, et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MAD IT-II) . ]  Am Coll Cardiol 2005 ;46: 17 12-20. (3) Rienstra M, Smit MD, Nieuwland W, et al. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. Am Heart J 2007; 153: 1 20-6. (4) Ellery S, Pakrashi T, Paul V, Sack S. Predicting mortality and rehospitalization in heart failure patients with home monitoring--the Home CARE pilot study 1 .  Clin Res Cardiol 2006;95:III29-III35. 
Discussion 
Discussion This thesis shows that response to cardiac resynchronization therapy (CRT) is still a problem. Predictors for response are not yet completely defined, though several parameters are now known to be of importance. Furthermore, since all landmark trials have been performed with sinus rhythm patients more data in atrial fibrillation patients are warranted. In the present discussion optimization of CRT and CRT in patients with AF is discussed Response to CRT Several large randomized trials have demonstrated that CRT improves clinical symptoms (New York Heart Association (NYHA) class, quality of life and 6 minute walking distance) and echocardiographic parameters. In addition, the number of hospitalizations for heart failure and all-cause mortality are reduced in comparison to optimal pharmacological treatment. 1 -5 Currently several definitions are used to determine response to CRT. On the one hand, response is defined by reverse remodeling, which is associated with an improvement in long term survival, and on the other hand clinical response (an improvement in NYHA class) is used, which may be most relevant from a patient's perspective.6•7 (Figure 1) However, NYHA class is subjective and is prone to a placebo effect, as it is not always associated with a significant objective improvement in exercise tolerance or hospitalization for heart failure. In several studies peak VO2 did not significantly improve in the control group despite improvement in NYHA class.3•8- 1 0  In accordance, our results found no correlation between NYHA response and peak VO/ 1 In addition, there is a low correlation between left ventricular remodeling and NYHA response.3•6·8 Bleeker et al. demonstrated in 144 patients treated with CRT that the agreement between clinical and echocardiographic response was only 76%. A total of 27% of patients who improved in NYHA class had no signs of left ventricular reverse remodeling. 8 Thus, a standardization of criterion for response to CRT is warranted. Predictors for response to CRT. Despite the current selection criteria, being NYHA III/IV despite optimal pharmacological treatment, LVEDD � 55mm, LVEF � 35%, QRS � 120 ms, still at least 30-40% of patients do not respond to CRT. 12 
Echocardiographic parameters that might optimize selection criteria. The rationale for CRT is that in patients with heart failure and disturbed electrical activation depolarization of the left ventricle free wall is significantly delayed compared with that of the right ventricle {interventricular dyssynchrony) and the interventricular septum (intraventricular dyssynchrony). A QRS duration � 120 ms is defined as a marker of ventricular dyssynchrony. Initial studies have shown that QRS duration correlates with interventricular dyssynchrony. 1 3- 1 5 In contrast to the interventricular dyssynchrony, intraventricular dyssynchrony correlates poorly with QRS duration. 1 3• 15• 19 Intraventricular dyssynchrony is absent in around one third of patients with an QRS duration � 120 ms. 
128 
□ NYHA improvement 4,61 ,82, 1 1 1 , 172, 174-177 
■ Combination NYHA, 6 MWD and Qol 3,5, 137, 173 
□ LVESVremodeling > 10% 108, 1 17, 1 52, Buck et al 
□ LVESVremodeling >15% 8,5 1 , 149, 1 8 1  
□ L VEF improvement > 5% 178 
■ combination NYHA, absence HF hospitalization 179, 1 80 Figure 1 Definition of response to CRT in current largest observational and randomized CRT studies. Only studies with more than 1 00 patients are shown Discussion Currently, it is taught that the intra-ventricular dyssynchrony predicts response to CRT. Several additional selection criteria have been postulated to determine intraventricular dyssynchrony and thus to improve response. Initial parameters to determine intraventricular dyssynchrony used conventional echocardiography (M-mode and two dimensional echocardiography). Currently, also more advanced modalities (tissue doppler imaging [TDI] , strain rate and 3 dimensional echocardiography) are used.20-35 (Table 1 )  
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Discussion Two dimensional echocardiography. Breithardt et al. and Kawaguchi et al. both developed an algorithm to determine intraventricular dyssynchrony in the apical 4 chamber view. 22•23 However, both techniques are restricted to dyssynchrony in a single plane. Currently, this method is not used anymore. Tissue Doppler imaging. Currently, tissue Doppler imaging (TDI) is the most common imaging modality employed to predict CRT response. TDI includes assessment of myocardial velocity in different myocardial regions and relates the timing of myocardial velocity to electrical activity, providing the electro­mechanical delay. In accordance with results found by Bax et al., our analysis revealed that the septal-to-lateral delay was a strong predictor for response to CRT. Furthermore, the diminishing of the septal-to-lateral delay during follow-up was associated with response (Figure 2).24•39-4 1 Others were able to demonstrate that the maximal delay between multiple segments was predictive for response.25•26 Currently, it has become possible to acquire a 3 dimensional color coded TDI of the left ventricle (LV).34•35 The size and positioning of the samples can be adjusted manually within the LV wall. This is a disadvantage since the observers have to identify the optimal peak systolic velocity curves. Therefore, a learning curve should be taken into account. Figure 2 Measurement of the septal to lateral delay. The sample volumes are placed in the basal parts of the septum and lateral wall. The delay in peak systolic velocity between the septum and lateral wall is the septal to lateral delay (marked) . 1 3 1  
Discussion Tissue synchronization imaging. In case of tissue synchronization imaging (TSI) the myocardium is color-coded based on automated time-to-peak systolic longitudinal velocity of each segment. This, in addition to quantitative analysis, allows rapid qualitative estimation of regional delay. By using this technique, Gorcsan et al. demonstrated in 29 patients who underwent CRT that a delay of � 65 ms between the anterior septum and the posterior wall using the apical long-axis view predicted LV reverse remodeling.30•42 There is a high correlation between automated assessment of LV dyssynchrony and manual assessment using TSI. This creates the possibility to omit the influence of the observer.43 However, the beneficial effects ofTSI above TDI haven not jet been demonstrated, and limitations are similar to TDI. Strain imaging. In case of strain imaging the percentage of myocardial deformation during systole is measured. Initial studies evaluating longitudinal strain report a low sensitivity and specificity.29•44 Using radial strain Dohi et al. were able to demonstrate that a difference of peak radial strain in the septum versus the posterior wall � 130 ms was associated with an immediate improvement in stroke volume.31 Thereafter, speckle tracking was developed. In case of speckle tracking a midventricular short-axis image is used to calculate radial strain from multiple circumferential points which are then compared to standard segments. The advantage of speckle tracking is that this measurement is not angle depended.32•45-48 It has been demonstrated that the time difference in peak septal wall to posterior wall strain � 130 ms predicts response to CRT.32 Response was more pronounced in patients in whom the LV lead was positioned at the site oflatest mechanical activation. Again the limitations are like TDI. Despite these advances in echocardiographic parameters to determine dyssynchrony, a randomized multi-center randomized trial (Predictors of response to CRT [PROSPECT]-trial) was not able to determine a specific echocardiographic parameter of dyssynchrony associated with response to CRT.49 It should be noted, however, that there was a high inter-observer variability. Currently, there are still new and sophisticated echocardiographic and magnetic residence imaging (MRI) techniques under investigation to improve selection techniques.48•50-58 Even so, in line with new echocardiographic techniques to improve response to CRT, we studied the predictive value of the total atrial conduction time (TACT). The TACT is the total duration of the of the atrial activation, and thus may serve as a measure of atrial structural remodeling.59•60 (Figure 3) Our analysis revealed that a longer TACT was associated with an increased risk of atrial fibrillation (AF) during follow-up. Possibly, the TACT is a marker of the severity of atrial remodeling.39 Indeed, we could show that in AF patients response was predicted by a shorter TACT, i.e. less severe atrial remodeling. The predictive value of TACT above left atrial size , which was not a predictor for response, may relate to the fact that the TACT not only is a measure of atrial size but also of conduction velocity, i.e. atrial structural remodeling. 1 32 
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Etiology of heart failure and response to CRT. The underlying etiology of heart failure influences response to CRT. Patients suffering from non-ischemic cardiomyopathy have a significantly larger chance to be a responder to CRT then patients suffering from ischemic cardiomyopathy.6 1-69 (Figure 4) An echocardiographic analysis from the Multicenter lnSync Randomized Clinical Evaluation (MIRACLE) study demonstrates that significant reverse remodeling and improvement in LV ejection fraction were significantly greater in non-ischemic cardiomyopathy patients.65 This difference is sustained during long term follow-up. In accordance, a predefined analysis from the CArdiac REsynchronization -Heart Failure (CARE-HF) study demonstrates that LV reverse remodeling is more pronounced in patients with non-ischemic cardiomyopathy. 68 There are several explanatory theories for this finding. Firstly, patients with an ischemic cardiomyopathy with a previous transmural myocardial infarction are limited with regard to optimal lead positioning. 66•70-73 Positioning of the left ventricular lead in scar tissue is associated with non-response.62•70 Secondly, in ischemic patients, dyssynchrony may be related to segmental wall motion abnormalities due to the presence of myocardial scar tissue or perfusion defects inabling resynchronization. Finally, the manner in which CRT influences myocardial oxygen consumption and myocardial blood flow is different 133 
Discussion between patients suffering from ischemic cardiomyopathy and non-ischemic cardiomyopathy. Linder et al. demonstrated that CRT improved ventricular efficiency and rendered more uniform blood flow distribution between myocardial walls in patients with non-ischemic cardiomyopathy but not in those with ischemic cardiomyopathy.74 
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0- ■ NICM □ ICM Figure 4 0 qf �0-� Influence of etiology of heart failure with regard to response to CRT. *P<0.05 * NICM = non ischemic cardiomyopathy, ICM = ischemic cardiomyopathy. Lead position and response to CRT Approximately 25-50% of chronic heart failure patients have an intraventricular conduction delay resulting in an abnormal activation sequence, which leads to delayed contraction of the last activated ventricular segments.75·76 The aim of CRT is to restore synchronous left ventricular contraction by pre-exciting the areas of delayed activation. To pre-excite the left ventricle, a pacing electrode is introduced into a suitable vein via the coronary sinus. Whether optimal placement of the pacing leads improves response is still undefined. 
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Discussion 
Left ventriculttr lead positi.oning and response to CRT. Theoretically the optimal position for the LV lead is postero-lateral, since in case of a left bundle branch block (LBBB) the postero-lateral wall is the last activated ventricular segment. Initial studies have shown the lateral or postero-lateral part of the left ventricle as the site that provides greatest acute haemodynamic benefit, particularly for the index of systolic performance (dP/dt).77-
81 Others showed that positioning of the LV lead in the lateral and postero-lateral coronary veins was associated with significant improvement in the functional capacity and greater improvement in the LV function when compared with the anterior coronary vein location.82 As demonstrated in chapter 5 ,  a larger horizontal interlead distance on the lateral X-ray predicted objective long-term response to cardiac resynchronization.40 In contrast the LV lead localization did not influence functional outcome in the Comparison of Medical Therapy, Pacing and defibrillation in Heart Failure (COMPANION) trial. However, analysis did indicate that positioning of the left ventricular lead in a lateral position was associated with a reduction in all-cause mortality. 83 This discrepancy between the COMPANION and our study may be influenced by the fact that in their analysis left ventricular lead position was defined according to the cardiac vein. As demonstrated by us, positioning of the left ventricular lead is difficult to determine by coronary vein evaluation. In a total of23% of the patients in whom the LV was thought to be positioned in the postero-lateral vein, evaluation of the thoracic X-ray revealed that the LV lead was positioned in the anterior vein.40 We describe that an optimal LV lead position is associated with a greater decrease of the septa! to lateral delay. 40 The finding that the intraventricular mechanical delay decreases in responders in contrast to the non-responders is in accordance with results found by others. 84•85 In addition to our findings Ypenburg et al. were able to demonstrate that pacing at the site oflatest mechanical activation resulted in superior echocardiographic response (defined as > 1 5% decrease in left ventricular end systolic volume) after 6 months of CRT and better prognosis during long-term follow-up.5 1 Despite overwhelming evidence of the importance of optimal placement of the left ventricular lead, this is often difficult due to the characteristics of the coronary venous anatomy, unacceptable electrical parameters in the target area, phrenic nerve stimulation , and/ or other technical difficulties. More research is needed with regard to optimal lead position, especially in patients who are non-responder to CRT. 135 
Discussion 
Epicardial placement of left ventricular lead. Historically, CRT involved direct surgical LV lead placement with transvenous insertion of the right atrial and right ventricular (RV) leads.86 Currently, the ability to secure the LV lead in a major cardiac vein through coronary sinus cannulation has become the standard procedure. However, due to the individual coronary venous anatomy or scar tissue the optimal position, i.e. the point of maximal delay, is frequently not achieved. The concordance between the LV lead tip and the region of maximal delay still is suboptimal, ranging from 55-65%.46•51 •87-89 Therefore, possibly in a selected number of non-responders to CRT with echocardiographically persistence of dyssynchrony during biventricular pacing, an epicardial placement of the LV lead may be beneficial. Mair et al. demonstrated that epicardial placement of the LV lead is associated with similar outcome as patients in whom a transvenous method is used.9° Further research is required with regard to optimization of LV lead position by epicardial placement of the LV lead. 
Right ventricular lead position and response to CRT. Currently, the optimal RV pacing lead location for CRT is still controversial. Van Gelder et al. were the first to describe a significant difference in hemodynamic parameters in 82 patients treated with CRT with placement of the RV lead in the apex being superior to placement in the right ventricular outflow tract.9 1  Accordingly, we found that placement of the RV lead in the apex was associated with higher echocardiographic response after 6 months of CRT. Possibly a larger interlead distance is created by placing the RV lead in the apex and the LV lead posterior or posterolateral, contributing to the observed superiority of apical RV pacing.40 Haghjoo et al, however, did not show any difference between RV lead placement in the apex or right ventricular outflow tract with regard to clinical outcome or reverse remodeling.92 However, they observed that the optimal RV lead positioning differed depending on the LV lead stimulation site. When the LV lead was positioned in the anterolateral vein, optimal position for the RV was the apex. On the other hand, when the LV lead was positioned in the posterolateral vein, positioning of the RV lead in the RV outflow tract was most beneficial. No association between RV lead placement and LV lead placement in the lateral vein was found. Judging these data, further research with regard to the optimal RV lead position needs to be performed to ensure optimal cardiac resynchronization therapy and probably may be of value to increase response in CRT patients. 
Multiple left ventricular leads. In order to increase the efficacy of CRT, dual-site pacing of the left ventricle has been proposed as an attractive option for resynchronization.93-99 In case of triple-site ventricular pacing two left ventricular leads are placed in the coronary sinus veins and one in the right ventricle. By fully surrounding the left ventricle a homogenous electrical excitation of the left ventricle may be provided. Currently, results regarding triple-site ventricular pacing are promising. Pappone et al. 136 
Discussion described that it was superior to single site left ventricular pacing in terms of acute hemodynamic parameters. 1 00 Thereafter, others were able to demonstrate that clinical improvement and reverse remodeling was significantly more pronounced .97•99 Leclercq et al. studied in 40 patients with moderate-to severe heart failure, a mean LV ejection fraction of 26 ± 11  %, and permanent atrial fibrillation requiring cardiac pacing for slow ventricular rate the beneficial effects of triple site ventricular pacing. Triple-site ventricular pacing resulted in a significant larger improvement of the LV ejection fraction (from 35 ± 11 % versus an improvement of 27 ± 11 %, p=0.001) and left ventricular reverse remodeling (LVESV 134 ± 75 cm3 versus 157 ± 69 cm3 , p=0.02). Despite these promising initial results, this therapy cannot be recommended in daily clinical practice until further larger randomized trials are performed. Especially, due to the fact that 2 instead of 1 LV lead increases the risk of complications and excessive battery consumption . Atrial fibrillation and cardiac resynchronization therapy Atrial fibrillation (AF) is the most common arrhythmia in heart failure. 10 1 • 1 02 The prevalence of AF is related to the functional heart failure NYHA class, varying from 5% for NYHA functional class I, 10-25% for classes II and III, and as high as 50% for class IV. 1 02• 1 03 However, cardiac resynchronization therapy in chronic heart failure patients with AF is still an area of controversy. 
Cardiac resynchronization therapy and atrial fibrilla.tion. Only one randomized trial has been performed to evaluate the efficacy of CRT in AF patients, the Multisite Stimulation in Cardiomyopathies in AF patients (MUSTIC-AF) trial. 104 In total 59 patients were randomized to univentricular pacing or biventricular VVIR pacing. A total of 39 patients underwent both 3-month treatment periods . Effective cardiac resynchronization significantly improved the mean 6 minute walked distance (374 ± 108 m versus 342 ± 103 m in univentricular pacing, p=0 .05). Even so, the peak oxygen uptake increased by 13% (p=0.04). Hospitalizations for heart failure decreased by 70%, and 85% of the patients preferred the biventricular pacing period (p<0.001). Despite the high drop out rate this randomized study suggests that in case of effective biventricular pacing, CRT also is useful in AF patients. Effective biventricular pacing was guaranteed through atrioventricular junctional ablation prior to implantation (63%) or atrioventricular conduction disturbances requiring permanent pacing (37%). In addition, observational trials have demonstrated that CRT also improves symptoms and reverse remodeling in AF patients (Table 2, Figure 5).2• 1 04-1 1 1  A meta-analysis by Upadhyay et al. showed similar improvement of cardiac function in AF patients compared to sinus rhythm patients. In the majority of AF patients permanent biventricular pacing was obtained by an atrioventricular junction ablation. 2•104-109• 1 12  137 
Discussion 
Atrioventricular junction ablation. Currently, the need for an atrioventricular junctional ablation in patients with AF treated with CRT still is a point of interest, with contradicting results. 1 08• 1 10, 1 1 1  Our results indicate that in case of effective continuous biventricular pacing, determined by exercise testing, there is not always a need for an atrioventricular junctional ablation. Optimal rate control medication ensuring continuous biventricular pacing is of pivotal importance for response to CRT in AF patients. This implies careful attention for heart rate also during moderate exercise as is demonstrated in chapter 4. 1 1  Short and long-term response and outcome are similar between AF and sinus rhythm patients (Figure 5). In accordance with our results others also demonstrated a favorable outcome in AF patients not treated with atrioventricular junction ablation. 109• 1 10 Khadjooi et al. demonstrated in 295 patients, 86 AF and 209 sinus rhythm patients, that during long-term follow-up of nearly 7 years mortality and morbidity are similar between AF and sinus rhythm patients. In contrast to these excellent results, others found that AF without an atrioventricular junction ablation was associated with non-response and poor outcome. 1 08• 1 1 1 • 1 13 Gasparini et al. compared the effects of CRT in 48 AF permanent AF patients without an atrioventricular junction ablation, with 114 AF patients which an atrioventricular junction ablation and 5 11 sinus rhythm patients. They found that only sinus rhythm patients and AF patients with an atrioventricular junction ablation showed significant LV reverse remodeling. 1 08 This was confirmed by Ferreira et al. 1 1 1  AF without an atrioventricular junction ablation predicted all cause mortality and hospitalization for heart failure. Importantly, the percentage of biventricular pacing documented by the device was frequently found to be less then 85% in their patients. Judging these contradicting results further investigation, preferably a randomized trial is needed to determine the precise role for atrioventricular junctional ablation in AF patients treated with CRT. (Figure 6) This is especially of importance since patients undergoing an atrioventricular junctional ablation become pacemaker dependent, complicating replacement procedures and even more importantly increasing the risk of complications in case of technical problems with the implanted device. So far it may be concluded that if continuous biventricular pacing is ensured, CRT is also effective in patients with AF. 138 
Discussion 
Long term prognosis to CRT. Only a limited number of retrospective studies have evaluated long-term outcome in patients with AF treated with CRT. Some studies observed that AF patients without an atrioventricular junctional ablation had a significantly higher cardiovascular morbidity and all-cause mortality rate. 1 1 1 • 1 1 3 In those studies, however, the percentage of biventricular pacing was low. Almost half of the AF patients had less than 85% of biventricular pacing precluding response to CRT. 1 1 3 Recent studies, however, demonstrated no significant difference in outcome between AF and sinus rhythm patients. In these studies, only a minority of the AF patients required an atrioventricular junctional ablation to ensure continuous pacing. The latter illustrates, on one hand, the difficulty and, on the other hand, the importance of optimizing rate control in AF patients, both in rest and during exercise. All in all, the above suggests that in hemodynamic stable heart failure patients AF does not influence response to CRT and outcome. However, it requires permanent biventricular pacing, also during exercise. This should be assessed according 
to a standardized protocol (Figure 7). 139 
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Discussion Pre implantation Peri-procedural Post implantation Follow-up Figure 7 Determine point of maximal dyssynchrony Positioning of the L V lead at the point of maximal dyssynchrony AV and VV optimalization for the individual patient Exercise test to evaluate heart rate response • heart rates exceeding the upper rate of the device • chronotropic incompetence Evaluate device characteristics • For AF burden • If possible thoracic impedance Can in part be performed by heart failure nurse • Electrocardiogram (ECG) to evaluate effective biventricular pacing • Evaluate whether adjustment of heart failure medication is required Flow chart how to treat and optimize the CRT recipitant. 144 
Discussion 
AF burden during CRT. Approximately 1 5% to 25% of the CRT recipitants develop AF during follow-up.1 14- 1 1 7 The definition of the presence of AF during follow-up is diverse, varying from AF documented by ECG to AF detected by the device. This is a major limitation, since AF detected by ECG or Holter underestimates the actual AF burden.1 14• 1 1 8 To effectively assess the prevalence of AF, registrations of devices should be considered as also asymptomatic short lasting AF episodes may influence prognosis. 1 19 The presence of previous AF is predictive for the development of AF during follow-up. These patients are more prone to have a recurrence of AF during follow-up. Analysis in our population of currently 29 1 patients reveals that patients with a history of AF significantly more often develop AF during follow-up. In total 55% of the patients with a history of AF developed AF burden during a median follow-up up of 29 months, in contrast to only 12% in patients with no previous history of AF. (Figure 8) At present the influence of AF burden during follow-up still needs to be elucidated. As demonstrated by us AF can reduce the effectiveness of CRT due to high intrinsic ventricular rate response, precluding effective biventricular pacing (Table 3).1 1 • 1 15• 1 20 It is not know whether CRT reduces the occurrence of AF. Initial non-randomized studies describe a reduction in AF burden during CRT. 1 1 6• 1 1 7• 1 2 1 • 1 22 Fung et al. demonstrated that patients treated with CRT significantly less frequently developed AF then a matched heart failure control group not treated with CRT (8% vs 3 1  %). Even so, others demonstrated a reduction but no abolishment of AF during short term follow-up. In 84 patients, of whom 33 (39%) patients had previous documented AF, CRT reduced AF burden from IO  hours to 4 hours per day. However, a post-hoc analysis from the CARE-HF study reported no significant difference in AF between patients treated with CRT versus those with optimal medical therapy ( 16% versus 1 4%). 1 14 We showed that response to CRT was associated with an decrease in occurrence of new-onset AF, which is in accordance with results by Borleffs et al. 1 1 5 However, no assumption can be made with regard to whether response to CRT is responsible for the decrease in development of new­onset AF, alternatively that the non-response to CRT is provocative for the development of new­onset AF. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) trial is the first study to determine whether the incidence of AF in patients with CRT can be reduced with atrial overdrive pacing. The I -year incidence of AF was comparable with the control group.1 23 Possibly the total atrial conduction time, diastolic parameters or intra/ inter atrial dyssynchrony can be helpful in selecting patients with the greatest risk of developing AF during follow-up. With the current development of home-monitoring devices, fortunately AF burden can be detected at an earlier stage. Currently, a large randomized trial is evaluating whether response to CRT can be improved by earlier detection and treatment of AF ( Clinical effecT of heart failure management via Home-monitoring with a focus on Atrial Fibrillation [effecT study] ). 145 
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Kaplan-Meier curve for time to first detected AF during follow-up in patients with a history of AF versus 
patients with no previously documented AF. Methods for optimizing device use and programming The implanted CRT device is enabled with several computerized techniques to improve its function in the heart failure patient. The device capabilities are able to determine the amount of biventricular pacing, to register the presence and amount of atrial arrhythmias, changes in lead impedance, heart rate variability, and thoracic impedance. Optimal device programming is essential to improve response. 
Atrioventricular delay programming. Device programming is crucial for response to CRT. An optimized AV-interval ensures optimal diastolic filling time and abolishes presystolic mitral valve regurgitation. Suboptimal AV-delay programming may result in up to 15% reduction in optimal cardiac output. 1 24-1 27 There are several techniques for AV-optimalization. Doppler echocardiographic methods as the velocity time integral over the mitral valve, the aortic valve, parameters derived by peak endocardial acceleration, impedance cardiography or by Doppler-derived left ventricular dP/dt and even finger plethysmography. 1 25• 1 28- 1 30 There is no agreement about which method should be used and 
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Optimal AV delay by volume clamp Figure 9 Correlation of AV optimalization by velocity rime integral micral valve versus volume clamp, larger point indicate more patients. 1 47 
Discussion Ventricular delay programming. The interventricular (VV) delay programming may compensate for less than optimal LV lead position by tailoring ventricular timing to correct for individual heterogeneous ventricular activation patterns commonly found in patients with LV dysfunction and CHE Sogaard et al. performed the first study evaluating the role of VV delay in CRT. 1 36 They demonstrated that the site and degree of mechanical asynchrony can differ between patients and is influenced by the underlying etiology of heart failure, being ischemic or non-ischemic. In total 21 patients with LBBB, QRS > 130 ms, NYHA class III or IV were studied. Post implantation the extent of dyssynchrony was evaluated by determining the delayed longitudinal contraction at several VV delay intervals. Optimal VV delay ranged between 12 and 20 ms in favor of the LV lead. After 3 months of follow-up the left ventricular ejection fraction significantly increased from 30 ± 5% to 39 ± 7% (p <0.01). Even so the lnsync III clinical study established the importance of VV timing. 1 37 This multicenter, prospective non-randomized study evaluates the clinical effectiveness of optimized CRT programming. In total 575 patients were included. A total of 359 patients underwent VV optimalization. All patients were reassessed at 1, 3 and 9 months after implantation. VV optimalization increased the stroke volume in 81 % of the patients. Patients with a history of myocardial infarction experienced significantly more improvement in stroke volume. Chronotropic incompetence and response to CRT. Chronotropic incompetence, defined as a failure to achieve 80% of the age predicted adjusted maximum heart rate, is associated with an increased risk of death. 1 38-14 1  Approximately 70% of patients with chronic heart failure suffer from chronotropic incompetence. 1 42 Due to the chronic increase in sympathetic activity a down regulation of the �-receptor occurs. The reduced myocardial sensitivity to the �-agonists leads to a reduction in heart rate response to exercise. 1 43-145 Furthermore, sinus node remodeling is frequently seen in patients suffering from chronic heart failure, resulting in a reduction in functional sinus node reserve. 146-148 In addition, negative chronotropic drugs, beta-blockers, amiodarone and digoxin worsen chronotropic incompetence. Only a few studies investigated this issue. Tse et al. were the first to determine that rate-adaptive pacing can improve exercise capacity in patients treated with CRT. 1 49 In accordance, we described that chronotropic incompetence was more frequently seen in non-responders to CRT especially in patients with sinus rhythm. 1 1  Chronotropy, therefore, should be assessed in all patients (figure 7). Heart rates exceeding the upper rate of the device. The aim of CRT is to restore synchronous left ventricular contraction by pre-exciting the areas of delayed activation. To ensure response to CRT effective biventricular pacing is required. Studies evaluating response to CRT use the device characteristics to determine the amount of 
148 
Discussion biventricular pacing . However, due to fusion pacing the amount of biventricular pacing can be overestimated by the device. As described by us and others the amount of effective biventricular pacing is clearly overestimated by the device counters when compared with a 24 hour Holter registration. 1 1 · 1 50 This overestimation of the percentage of biventricular pacing creates a major limitation with regard to CRT in AF patients . Therefore, an exercise test should be performed routinely to determine whether biventricular pacing is adequate during (moderate) exercise (Figure 7) . 1 1  We defined moderate exercise as 25% of the maximal achieved exercise duration. This severity of exercise was chosen since these exercise levels correspond with exercise levels made by the patient during daily activities. 1 5 1  In case of inadequate biventricular pacing the electrocardiogram (ECG) changes significantly (Figure 10). Judging the ease to determine inadequate pacing with an ECG, it is of the utmost importance 
to inspect the ECG every time. Even so, by exercise testing other lead problems can easily be detected. For instance, one of our patients who suffered from severe diaphragmatic stimulation . Therefore the pacing threshold of the left ventricular lead was adjusted . During the exercise test, routinely performed in our center, 2 months after implantation to determine effective biventricular pacing, it was detected that the left ventricular pacing was compromised in certain positions. (Figure 11) During bending the ECG does not show biventricular pacing but right ventricle pacing only. The percentage ofbiventricular pacing can also be undermined by frequent premature ventricular beats . (Figure 12) Since cardiac resynchronization therapy has become an established therapy for patients with advanced heart failure further prospective studies are warranted to determine how optimal device utilization can improve response. Long-term follow-up Randomized trials have demonstrated that CRT improves clinical symptoms (NYHA class for heart failure, 6 minute walked distance, quality of life, hospitalization for heart failure and mortality) and echocardiographic parameters (systolic function, left ventricular size and mitral valve regurgitation). 1 ·5 However, limited data are available about long term echocardiographic response to CRT. 
Long-term echocardiographic response to CRT. Clinical and echocardiographic follow-up in most studies is relatively short . Therefore, it is unknown whether reverse LV remodeling is sustained during long-term follow-up. The long-term echocardiographic follow-up of the MIRACLE trial is the first randomized trial to demonstrate that reverse remodeling is sustained during long-term follow-up.65 Reverse remodeling was most prominent during the first 6 months after initiation of CRT to be maintained thereafter. In accordance we and others describe that echocardiographic response is sustained during long-term follow-up. 1os, 152 
149 
Discussion Striking is that most studies evaluating long-term response to CRT are mainly performed in studies evaluating response between AF and sinus rhythm patients. An important finding is chat during long-term follow-up the response rate is similar between sinus rhythm and AF patients. 1 os- 1 1 1 , 1 1 3, 1 s2 Table 3 .  Incidence of AF burden and CRT Study Nr of patients Follow up Primary Outcome Comments Design Fung et al. 1 1 6 Hoppe et al. 1 14 Hugi et al. 1 2 1  n=72 (36 CRT) 36 matched controls Observational n=8 1 3  sub analysis CARE-HF 409 CRT, 404 controls n=84 (84 CRT) Observational Adelstein et al. 122 n=8 1 (54 CRT) Fung et al. 1 1 7 Borleffs et al. 1 1 5 Buck et al. 27 matched controls Observational N =97 (97 CRT) Observational N =223 (223 CRT) 0 bservational N= 1 20 ( 1 20 CRT) Observational 3 years 29 months 3 months 1 year 3 years 32 months 26 months CRT reduced risk of new No history of AF onset AF (annual incidence AF detection relied on 2.8% vs ECG, event recorders 1 0 .2 %, p=0.025).  and 24 hours holter examination There was no difference in new 20% patients history of onset AF between CRT and AF control patients ( 1 6% versus AF detection relied on 14%, p=0.79) . ECG AF detection by the device was considerably higher (39%). AF burden gradually decreased AF detected by the device during CRT from 9.88 ± 39% of patients had a 1 2.61  hours/ day in the first history of AF month to 4.2 ± 9.24 hours/ 4 patients had AF at day after 3 months, even so implantation patients with AF episode decreases (3 1 % versus 1 5  % ) . There was no significant 37% control vs 35% CRT difference in AF burden history of AF between CRT and control AF detected by the device patients (failed CRT implantation) . CRT responders had a trend to a longer AF free follow-up. CRT patients with reverse No AF history atrial remodeling and AF detected by the device improvement in left atrial ejection fraction significantly less frequently develop new onset AF ( 12,8% versus 40%) . Magnitude of LV reverse No AF history remodeling is significantly less AF detected by the device in patients with new-onset AF. Responders significantly less No AF history frequently develop new-onset AF detected by the device AF during follow-up (6% versus 28%) . AF = atrial fibrillation; CRT = cardiac resynchronization therapy; ECG = electrocardiogram; LV = left ventricle 1 50 
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Electrocardiogram during exercise test of a patient in whom left ventricular pacing was compromised in 
certain positions. Baseline electrocardiogram at the start of exercise test (A) showing effective biventricular 
pacing, and ECG during exercise when bent forward, showing only right ventricular pacing (B). 152 
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CASE V6 . 51 25mm/o lOmm/mV SOHz O . OlHz FRF+ HF (V5 , V4 )  Figure 12 Ventricular extra systoles compromising left ventricular pacing. (A over view of the device characteristics, B ECG showing the frequent ventricular extra systoles) . 153 
Discussion Future perspectives 
CRT in NYHA IL An unanswered question is whether CRT may improve prognosis in patients with depressed systolic function but minimally symptomatic heart failure. An initial small non-randomized, prospective study revealed that CRT could also be effective in patients with less severe symptomatic heart failure. 1 53 Analysis revealed that NYHA II patients had a similar response compared to NYHA III/N patients. Only 8% of the patients developed a progression of heart failure during the follow-up. The MIRACLE ICD II trial is a randomized trial comparing the beneficial effect of CRT in patients with NYHA class II. 1 54 This study showed that CRT did not alter exercise capacity in these patients. However it resulted in significant LV reverse remodeling (a decrease in LV end systolic volume and an increase in LVEF). In accordance, results from the REVERSE trial demonstrated that CRT reduces the risk for heart failure hospitalization and LVESV 1 55 Currently the long-term results of the REVERSE trial and the results of the MADIT­CRT trial are still awaited. 1 56 
CRT in patients with a narrow QRS complex. Whether cardiac resynchronization therapy is beneficial in patients with mechanical dyssynchrony despite a narrow QRS complex is also unknown. A meta-analysis by Jeevanantham et al. 1 57  found that patients with a narrow QRS complex and evident mechanical asynchrony also benefited from CRT with a significant improvement in NYHA class, LVEF and 6 minute walked test. Further investigation of this group of patients is, certainly warranted. 
CRT in patients with an indication for permanent pacing. Most patients with permanent pacemakers tolerate RV pacing well. 1 58 However, induction of ventricular dyssynchrony by RV pacing may have adverse consequences. Chronic RV pacing is associated with a higher incidence of heart failure and AF than atrial based pacing modalities. 1 59-1 63 The detrimental effect of RV stimulation is more dramatic in patients with LV dysfunction. 1 6 1 • 1 63• 1 64 In the Duel Chamber and VVI Implantable Defibrillator (DAVID) and the Multicenter Automatic Defibrillation Implantation trial II (MADIT-11) trial, RV stimulation significantly increased the risk for the combined endpoint of heart failure hospitalization or death. 1 6 1 , 1 64 The Post AV Nodal Ablation Evaluation (The PAVE) study demonstrated in 184 patients requiring AV node ablation due to chronic atrial fibrillation with rapid ventricular rates, that CRT significantly improved the 6 minute walked distance (31 % above baseline compared to 24% in patients randomized to RV pacing). 1 65 Patients with an ejection fraction :5 45% or with NYHA class II/III symptoms appeared to have a greater improvement then patients with a normal systolic function. This difference was mainly due to a decline in the 6 minute walked distance in the RV pacing group. The Homburg Biventricular Pacing Evaluation (HOBIPACE) trial 1 54 
Discussion is a prospective randomized crossover-trial comparing biventricular pacing with conventional RV pacing in patients with LV dysfunction and a standard indication for pacing. 1 66 In total 30 patients were included. Cardiac resynchronization therapy reduced LV end systolic volume by 17% (p<0.001), increased LVEF by 22% (p<0.0002), and peak oxygen consumption by 12% (p<0.0003). 1 66 Currently the results of the Biventricular versus right ventricular pacing in patients with AV block (BLOCK-HF) trial and Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BIOPACE) trial are awaited to further elucidate the best treatment for patients requiring ventricular pacing. 167• 1 68 In the BLOCK-HF trial patients with LVEF :::; 50%, NYHA functional class 1-111, a class I or Ila indication for a permanent pacemaker, and atrioventricular block, a Wenkebach block or PR > 300 ms when pacing at 100 beats per minute. 168 All patients will receive a CRT pacemaker, with randomization to RV pacing versus CRT. The primary endpoint is a combined endpoint of overall mortality, heart failure related urgent care, and changes in LV volumes. The BIOPACE trial will prospectively evaluate the long-term effects of RV pacing versus biventricular pacing in patients with a high-degree atrioventricular block. 1 67 Randomization will depend on the LV systolic function. The primary endpoint is survival, quality of life and the distance covered in 6 minute walked after 24 months of follow-up. Conclusion Cardiac resynchronization therapy has become a corner stone in the treatment of the chronic heart failure patient. All-cause mortality is significantly reduced since the introduction of CRT. The largest randomized trials, the COMPANION and CARE-HF demonstrated a reduction of approximately 9% in all-cause mortality. This means that 13 patients have to be treated with CRT during 2 years to save 1 life. Despite these impressive results, however, 20-40% of patients are a non-responder to CRT. Most studies evaluating the effect of CRT are performed in sinus rhythm patients. Currently more and more evidence becomes available that AF patients also benefit from cardiac resynchronization therapy. The need for an atrioventricular junction ablation in AF patients treated with CRT is still a point of interest. Our results imply that in case of permanent biventricular pacing, also during exercise, there seems not always a need for an atrioventricular junction ablation. Evaluation of percentage biventricular pacing, however, is warranted, especially in these patients. The device characteristics can overestimate the percentage of biventricular pacing. Therefore an exercise test should be used. Approximately, 40% of the patients treated with CRT develop AF during follow up, being new onset AF in 15-25%. AF burden during follow-up can reduce the effectiveness of CRT due to high intrinsic ventricular rate response. Home monitoring can help to detect AF earlier after start. 1 55 
Discussion As demonstrated in this thesis, optimal pharmacological treatment and optimal programming of the device are essential to improve further response to CRT. Specific attention should be paid to the point of maximal dyssynchrony and it is of the utmost importance that the LV lead is placed at the point of maximal dyssynchrony. In case of non-response, despite optimal device programming, further analysis need to be performed to determine whether the intraventricular dyssynchrony is still present. Possibly, in these patients an optimal lead position needs to be obtained, e.g. by epicardial lead placement. 156 
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English summary 
English summary The general introduction of this thesis provides a description of the rationale behind cardiac resynchronization therapy ( CRT) and a general overview of the clinical results. The beneficial effects of CRT have been confirmed by large randomized clinical trials. Cardiac resynchronization therapy results in an improvement in clinical symptoms (New York Heart Association (NYHA) class, quality of life and 6 minute walking distance) and an improvement in echocardiographic parameters (left ventricular (LV) ejection fraction, LV volume and mitral valve regurgitation). Cardiac resynchronization therapy reduces the number of hospitalizations for decompensated heart failure and all-cause mortality compared to optimal pharmacological treatement. Currently, the guidelines state that CRT is recommended in patients with symptomatic heart failure (NYHA class III-IV) despite optimal pharmacological therapy, impaired LV ejection fraction (<35%), LV end diastolic diameter � 55  mm, and electrical dyssynchrony (QRS > 120 ms). However, despite the current selection criteria, a consistent number of patients do not respond to CRT. When response to CRT is defined using clinical parameters (e.g. improvement in NYHA class or quality of life) the prevalence of non-responders is approximately 30% and when echocardiographic parameters (LV reverse remodeling, improvement in LV ejection fraction) are applied, the number of non-responders is approximately 40%. The results on which the guidelines are funded are based on clinical trials with patients in sinus rhythm (SR). Patients with atrial fibrillation (AF) were excluded from the landmark trials. However, AF and chronic heart failure (CHF) often coexist. The prevalence of AF is relatively high, and related to the functional heart failure NYHA class, varying from 5% for NYHA functional class I, 10-25% for classes II and III, and as high as 50% for class IV. Smaller non­randomized trials have shown promising results in AF patients; however the necessity for an atrioventricular junctional (AVJ) ablation is currently unknown. The aim of the current thesis was to study the influence of AF on response to CRT. (part I) Secondly, we studied whether by optimization of device characteristics response can be improved. (part II) 
Beneficial effect of CRT in AF patients In chapter 1 response to CRT was evaluated in AF and SR patients. A total of 114 patients were included based on established selection criteria for CRT. A total of 56 ( 49%) patients had AF (23 current AF and 33 earlier AF), the remaining 58 (51 %) patients had no history of AF. Response was comparable between patients with current and earlier AF (19 [58%] versus 13 [56%]) and between patients with and without AF (32 [57%] versus 32 [55%]). To determine whether the degree of structural atrial disease influenced response to CRT the influence of the total atrial conduction time (TACT) was evaluated. The TACT was similar between AF and no-AF patients. In AF patients the TACT predicted the occurrence of AF during follow-up. Multivariate analysis revealed the importance of the TACT. In AF patients predictors for response were a shorter TACT and an IVMD > 40 ms. In no-AF patients predictors for 176 
English summary response were non-ischemic cardiomyopathy, a lower creatinine, a higher systolic blood pressure and a posterior positioning of the left ventricular lead. AF burden significantly more frequently occurred in AF patients (35 [62%] versus 14 [24%] , p<0.001). In AF patients, AF burden did not influence response, in contrast to no-AF patients in whom new-onset AF was associated with non-response. It is difficult to determine whether new-onset AF post CRT is a consequence or a cause of hemodynamic deterioration, i.e. failure to CRT. On the one hand, AF post-CRT may reduce effective biventricular pacing, due to high heart rates during AF leading to failure of CRT. On the other hand deterioration of the hemodynamic situation may also induce AF. This finding implies that during follow-up, the presence of AF should be carefully monitored as it either may be a marker of deterioration of the hemodynamic situation due to progression of the disease, or the other way around, may eventually lead to an impaired hemodynamic situation. Cardiac resynchronization therapy is still a controversy in AF patients, in chapter 2 the long-term response to CRT was compared between AF and sinus rhythm patients. In total 214 patients were studied, of whom 94 (44%) were known with AF, the remaining 120 (56%) patients had no history of AF. Mean follow-up duration was 27 months. Only 8 AF patients underwent an atrioventricular junction (AVJ) ablation. Echocardiographic response was comparable between AF and SR patients at 6 months, 1 year and 2 years (66%, 73% and 65% versus 64%, 71 % and 63%, all not statistically different). Even so, NYHA response was comparable (71 %, 62% and 61 % in AF patients versus 77%, 73% and 72% in SR patients at 6 months, 1 year and 2 years, all not statistically different). Cumulative event rates for the composite endpoint (all-cause mortality, cardiac transplantation or hospitalization for heart failure) were comparable between AF and SR patients. Atrial fibrillation, current or previous, did not influence mortality during follow-up. Thereby notifying that outcome is similar between AF and SR patients even without AVJ ablation, AF patients meeting all the criteria for cardiac resynchronization therapy should therefore be considered for CRT, and in case of adequate rate control with pharmacological therapy there is no need for an AVJ ablation, which should be held as a last resort. The aim of chapter 3 is to examine whether CRT prevents new-onset AF. The annual incidence of AF in patients with CHF is approximately 5%. New-onset AF can undermine the effectiveness of CRT, e.g. due to the high intrinsic ventricular rate response permanent biventricular pacing can be compromised. We studied 120 CRT recipitants with no previous documented AF prospectively. Clinical evaluation included NYHA class and echocardiographic evaluation of LV reverse remodeling. The device characteristics were carefully studied to determine whether AF occurred during follow-up. Atrial fibrillation was defined as a high atrial rate > 200 bpm, during > 30 seconds. Responders significantly less frequently developed new-onset AF (5 [6%] versus 12 [28%] , p=0.001), during a mean follow-up of 26 months. Left atrial volume significantly decreased in 
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English summary responders, possible the improvement in LV function and thus the decrease in LV end systolic pressure caused a decrease in atrial overload thereby decreasing the risk of developing AF during follow-up. Concluding, the prevalence and incidence of new-onset AF is reduced in responders to CRT. Part II Predictors for response to CRT The aim of chapter 4 was to evaluate the role of exercise-induced loss of bi ventricular stimulation and chronotropic incompetence during exercise. One hundred and forty four consecutive patients were included. After 6 months 86 (60%) patients were a responder to CRT. Response was comparable between AF and SR patients (e.g. 42 [49%] responders with AF versus 44 [57%] SR patients, p=0.50). All patients underwent an exercise test 6 months after CRT implantation; heart rate response during exercise was investigated by assessing the presence of continuous biventricular pacing and chronotropic incompetence. Responders hardly ever exceeded the upper rate of the device during moderate exercise (2 [3%] versus 13 [22%] , respectively, p <0.0001). The influence of heart rate exceeding the upper rate of the device during moderate exercise was restricted to patients with AF (9 (32%) patients with AF, versus 6 (5%) patients with SR, p<0.0001). The percentage of biventricular pacing recorded by the device was only marginally lower in patients in whom the heart rate exceeded the upper rate of the device during moderate exercise (99% [ 60-100] versus 98% [37-100] , p=0.003). This may relate to an overestimation of the true amount of biventricular pacing due to fusion pacing. Only during an exercise tests loss of biventricular pacing may become apparent, which can be easily detected on the electrocardiograms. Even so, responders significantly less frequently were chronotropic incompetent: 9 (10%) responders versus 21 (36%) non responders, p < 0. 03. The influence of chronotropic incompetence on response was restricted to patients with SR (7 [ 10%] of the responders versus 18 [ 42 % ] of the non-responders, p<0.0001), in contrast to patients with AF (2 [15%] of the responders versus 3 [20%] of the non-responders, p=0.50). Multivariate analysis revealed that heart rate exceeding the upper rate during moderate exercise is an independent predictor for non-response to CRT, possible due to loss of biventricular stimulation. Monitoring and if needed an adjustment of the device pacing features, e.g adjustment of the pharmacological treatment may therefore help to increase response to CRT. Therefore, in CRT patients we encourage dose examination of exercise tests, and subsequently adequate reprogramming of the device if necessary, e.g. adding more negative chronotropic drugs or adjustment of the upper rate of the device. Furthermore, an exercise test might be a helpful tool to determine whether an AVJ ablation is needed to ensure optimal biventricular pacing in the individual AF patient. The influence of lead positioning on success of CRT was studied in chapter 5 .  According to the patho-physiology the desired position for the left ventricular lead is posterolateral, therefore 178 




Nederlandse samenvatting De intraductie van die praefschrift geeft een overzicht van het werkingsmechanisme van cardiale resynchranizatie cherapie (CRT) en beschrijft de klinische resulcaten van CRT in patienten met chranisch harcfalen. De positieve effecten van CRT zijn onder meer een verbetering in klinische symptomen (zoals NYHA functionele klasse, kwaliteit van leven) en een verbetering van echocardiografische parameters (linker ventrikel (LV) ejectiefractie, LV volumina en micralis klep insufficientie). Bovendien leidt CRT tot een afname van het aantal opnames voor gedecompenseerd harcfalen en van de mortaliteit in vergelijking met patienten die alleen warden behandeld met optimale farmacologische cherapie. De richtlijnen bevelen CRT aan bij patienten met sympcomatisch harcfalen (NYHA III/IV) ondanks optimaal farmacologische behandeling, een verminderde LV ejectiefractie (< 35%) en tekenen van elektrische dissynchranie (QRS > 120 ms). Echter, desondanks indrukwekkende resulcaten blijkt er een groep patienten te zijn die niet verbeterd na CRT. Wanneer response op CRT wordt gedefinieerd als een verbetering in klinische symptomen (bijvoorbeeld verbetering in NYHA klasse of kwaliteit van leven) clan is het percentage non-responders ongeveer 30% en wanneer non-response wordt gedefinieerd met behulp van echocardiografische parameters (LV reverse remodeling of verbetering in LV ejectiefractie) clan ligt het percentage non-responders rand de 40%. De richtlijnen zijn gebaseerd op studies in patienten met sinus ritme. Patienten met atriumfibrilleren (AF) werden geexcludeerd uit de grate studies. Atriumfibrilleren is een veel voorkomende harcricme scoornis is in patiencen met chranisch harcfalen. De prevalentie van AF neemt toe naarmate er sprake is van ernstiger harcfalen, varierend van 5% voor patienten die zich in NYHA klasse I bevinden, 10-25% voor klasse II en III en zelfs 50% voor klasse IV Enkele niet gerandomiseerde studies laten veelbelovende resulcaten van CRT in patienten met AF zien. Of een atrio-ventriculaire knoop ablatie ge'.indiceerd is in patienten met AF die middels CRT warden behandeld is nog onduidelijk. Hee doel van die praefschrift is om te onderzoeken wat de invloed van AF is met betrekking tot response op CRT (part I). Ten tweede hebben we bestudeerd of door optimalisatie van het apparaat response op CRT verbecerd kan warden. Cardiale resynchronizatie therapie in patienten met AF. In hoofdstuk 1 vergelijken we response op CRT Cussen patienten met AF en sinus ritme. In totaliteit zijn 114 patienten gelilcludeerd, inclusie vond plaats volgens de huidige richtlijnen. In totaal hebben 56 ( 49%) van de patienten AF (23 AF op her moment van implantatie en 33 eerder gedocumenteerd AF), de overgebleven 58 (5 1 %) patienten hebben nooit eerder gedocumenceerd AF (no-AF). Response was vergelijkbaar Cussen patienten met huidig en eerder AF (19 [58%] versus 13 [56%]) en tussen patiencen met en zonder AF (32[57%] versus 32 [55%]). Om te beoordelen of de mate van atriale 'remodelling' response op CRT belilvloedt hebben we gekeken naar de invloed van de totale atriale activatie tijd (TACT) op response. De TACT was 
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Nederlandse samenvatting vergelijkbaar tussen patienten met en zonder AF. De TACT voorspelde her optreden van AF gedurende follow up in patienten met eerder gedocumenteerd AF. Multivariate analyse toonde her belang van de TACT aan voor response in patienten met AF. In patienten met AF bleek een kortere TACT en een inter-ventriculaire mechanische vertraging voorspellend voor response. In patienten zonder AF waren een non-ischemsche cardiomyopathie, een betere nierfunctie, een hogere systolische bloeddruk en positionering van de LVI draad posterior voorspellend voor response. Gedurende follow-up werd AF significant vaker gezien in patienten met eerder gedocumenteerd AF (35 [62%] versus 14 [24%] , p<0.0001). In deze patienten had her optreden van AF gedurende de follow-up geen invloed op response. Daarentegen was her nieuw ontstaan van AF geassocieerd met non-response op CRT. Her is onduidelijk of her nieuw ontstane AF een consequentie of een gevolg is van hemodynamische achteruitgang, ie falen op CRT. Aan de ene kant kan AF er toe leiden dat her percentage biventriculair pacen in her gedrang komt, door de hoge ventriculaire volg frequentie, maar anderzijds kan her ook zijn dat door de achteruitgang van de hemodynamische situatie her AF juist ontstaat. Deze bevinding impliceert dat her belangrijk is om gedurende de follow-up goed op re letten of er AF ontstaat, aangezien her als een marker van achteruitgang van her klinisch beeld gebruikt kan worden of anderzijds juist kan lijden tot een verslechterde hemodynamische situatie. Her gebruik van CRT is nog controversieel in patienten met AF, in hoofdstuk 2 beschrijven we de lange termijn resultaten van patienten met AF vergeleken met sinus ritme patienten. In totaliteit werden 214 patienten gei"ncludeerd, 94 AF patienten en 120 no-AF patienten. De gemiddelde follow-up duur was 27 maanden. Slechts 8 AF patienten hadden een atrio-ventriculaire knoop ablatie ondergaan. Gedurende lange termijn follow-up was echocardiografische response vergelijkbaar tussen patienten met AF en sinusritme (66%, 73% en 65% versus 64%, 71  % en 63% op 6 maanden, 1 jaar en 2 jaar, niet statistisch verschillend). Ook NYHA response was vergelijkbaar (71 %, 62% en 61 % in AF versus 77%, 73% en 72% in sinus ritme patienten). Her optreden van her gecombineerde eindpunt (mortaliteit, hart transplantatie of hartfalen hospitalisatie) was vergelijkbaar tussen AF en sinus ritme patienten. AF bei"nvloede her optreden van her eindpunt niet. Aangezien her resultaat van CRT vergelijkbaar is tussen patienten met AF en sinusritme, waarbij slechts een minderheid van de AF patienten een atrio-ventriculaire knoop ablatie heeft ondergaan, pleit dit ervoor dat AF patienten ook in aanmerking dienen te komen voor CRT. Hierbij is her belangrijk om via farmacologische behandeling zorg re dragen voor adequate rate controle. Een atrio-ventriculaire knoop ablatie client niet zomaar verricht te worden. 
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Nederlandse samenvatting In hoofdstuk 3 hebben we bekeken of CRT het optreden van nieuw AF kan voorkomen. De jaarlijkse incidentie van AF in patienten met hartfalen is ongeveer 5%. Nieuw AF kan de effectiviteit van CRT teniet doen, een hoge ventriculaire volg frequentie ten gevolge van het AF kan het percentage biventriculair pacen in het gedrang brengen. We hebben 120 patienten met nooit eerder gedocumenteerd AF prospectief vervolgd. Atriumfibrilleren werd vastgesteld aan de hand van het apparaat, AF werd gedefinieerd als een hoog atriaal ritme van >200 slagen per minuut gedurende meer clan 30 seconden. Responders op CRT ontwikkelden significant minder vaak nieuw AF (5 [6%] versus 12 [28%] , p=0.001). Linker atrium volume nam significant af in responders, mogelijk ten gevolge van een verbetering van de LV functie en dus een afname van de LV eind diastolische druk en dus ook een afname van de atriale belasting, waardoor het risico op AF wordt verminderd. Concluderend de prevalentie en incidentie van nieuw AF neemt af in responders op CRT. Deel II Voorspellers voor response op CRT. In hoofdstuk 4 evalueren we of het hartfrequentie beloop gedurende inspanning van invloed is op response. Hierbij hebben we gekeken naar de invloed van chronotrope incompetentie en de invloed van hartfrequenties die de bovengrens van het apparaat overstijgen gedurende gematigde inspanning. Honderd vier en veertig patienten werden ge'includeerd. Na 6 maanden waren 86 (60%) patienten een responder op CRT. Het response percentage was vergelijkbaar tussen AF en sinus ritme patienten (te weten 42 [49%] patienten met AF versus 44 [57%] sinus ritme patienten, p=0.50). Alie patienten ondergingen een inspanningsonderzoek 6 maanden na CRT implantatie, hartfrequentie beloop gedurende inspanning werd onderzocht, hierbij werd gekeken naar de aanwezigheid van continue biventriculair pacen en chronotrope incompetentie. Het percentage biventriculair pacen kwam bijna nooit in gedrang bij responders op CRT, slechts in enkele patienten steeg de hartfrequentie boven de boven de volgfrequentie grens van de CRT gedurende gematigde inspanning (2 [3%] in responders versus 13 [22%] in non-responders, p<0.0001). Hart frequenties die boven de volgfrequentie van het apparaat uitstegen bleek voornamelijk voor te komen in patienten met AF. Het percentage biventriculair pacen vastgesteld aan de hand van het CRT apparaat was slechts marginaal lager in patienten waarbij de hartfrequentie gedurende gematigde inspanning boven de volgfrequentie van het CRT apparaat ging (99% [60-100] versus 98 % [37-100, p=0.003). Mogelijk dat het apparaat het werkelijke percentage biventriculair pacen overschat door van het optreden van fusie pacing. Via een inspanningsonderzoek kan aan de hand van de ECG's het optreden van de te snelle volgfrequenties gemakkelijk vast gesteld worden. 1 84 
Nederlandse samenvatting Chronotrope incompetentie werd minder vaak gezin in responders (9 [10%] van de responders versus 21 [36%] van de non-responders, p<0.03). Het optreden van chronotrope incompetentie was vooral van invloed in sinus ritme patienten (7 [10%] versus 18 [42%] , p<0.0001), in tegenstelling tot AF patienten (2 [15%] versus 3 [20%] , p=0.50). Multivariate analyse toont aan dat het optreden van hartfrequentie boven de grens van het apparaat gedurende gematigde inspanning geassocieerd is met non-response, waarschijnlijk ten gevolge van het verlies van effectief biventriculair pacen. Monitoring en indien noodzakelijk aanpassen van de device karakteristieken of aanpassing van de medicamenteuze behandeling is gefodiceerd om response op CRT te verbeteren. Daarnaast kan een inspanningsonderzoek mogelijk assisteren in de beslissing of een atrio-ventriculaire knoop ablatie gefodiceerd is in de individuele AF patient. De invloed LV draad positie met betrekking tot response op CRT hebben we bestudeerd in 
hoofdstuk 5. Aan de hand van de patho-fysiologie is de optimale positie voor de LV draad postero-lateraal, aangezien dit segment het laatst wordt geactiveerd in het geval van een linkerbundeltak-blok. Hoewel, dit is niet empirisch aangetoond, een kleine hemodynamische studie heeft aangetoond dat een posterior positionering van de LV draad geassocieerd is met een grotere hemodynamische verbetering. We hebben dit onderzocht in 174 CRT patienten. Na 6 maanden waren 95 (55%) van de patienten een responder op CRT. Een grotere horizontale afstand tussen de rechter en LV draad gemeten op de laterale X-thorax was voorspellend voor response, dit komt overeen met een posterior positionering van de LV draad. Daarnaast was een posterior positionering van de LV draad geassocieerd met een grotere afname van de intraventriculaire vercraging (gemeten middels de septal tot lateral delay). Analyse toonde aan dat her lastig kan zijn om tijdens de implancatie de precieze positionering van de LV draad te beoordelen. In een significant deel van de patienten (23%) bleek er een discrepantie tussen de voorspelde LV draad positie middels coronair veneus angiogram en de uiteindelijke LV draad positie bepaald middels X-chorax. Die wordt waarschijnlijk veroorzaakt door de variabele veneuze anatomie. Door aanpassing van de huidig gebruikte opnames die worden gebruikt voor de LV draad positionering, van links anterior oblique 30 ° -40" naar links anterior oblique 90" kan de meest posterior gelegen vene beter in beeld gebracht worden. Concluderend positionering van de LV draad is van her hoogsce belang, in geval van twijfel ten aanzien van LV draad positie moet verder gezocht worden of het wel de optimale positie is. 
Hoofdstuk 6 is een casus over hoe optimaal gebruik van her apparaac de behandeling van de individuele patient kan verbeteren. In deze casus bespreken we een patient die zich presenteerc in verband met terechce ICD shocks. Waarschijnlijk was de VT uitgelokt door de progressie van her harcfalen ten gevolge van een persisterende acriale flutter met een hoge ventriculaire volg frequentie. Door her inschakelen van de OptiVol alarm, zouden de ICD shocks mogelijk voorkomen hebben kunnen worden door een eerdere interventie. 
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Nederlandse samenvatting In de discussie van dit proefschrift worden de resultaten van onze studies vergeleken met wetenschappelijke literatuur. Verder worden toekomstige ontwikkelingen besproken. Cardiale resynchronizatie therapie is niet meer weg te denken in de behandeling van de hart falen patient. Alhoewel is het van belang om elke patient als een individu te behandelen en te beoordelen of het apparaat optimaal is afgesteld voor de individuele patient. Of CRT even effectief in AF patienten is als in sinus ritme patienten is nog niet helemaal duidelijk, onze onderzoek toont aan dat in het geval van optimaal medicamenteuze rate controle er geen noodzaak is tot het verrichten van een atrioventriculaire knoop ablatie. Ook dit moet voor elk individu worden beoordeeld. 
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Dankwoord 
Dankwoord Promoveren doe je niet alleen, er zijn velen betrokken geweest bij de totstandkoming van dit proefschrift. Zonder iemand te kort te willen doen, wil ik een aantal mensen persoonlijk bedanken. Allereerst mijn eerste promotor prof. Dr. LC. van Gelder. Beste Isabelle, ik wil je bedanken voor de plezierige samenwerking. Je kennis van de literatuur over boezemfibrilleren en cardiale resynchronizatie therapie en je inzet om een artikel of protocol te schrijven waren onmisbaar. Ten tweede wil ik mijn tweede promotor prof. Dr. D.J. van Veldhuisen bedanken. Beste Dirk Jan, ik wil je bedanken voor je enthousiasme als er weer een artikel geaccepteerd was, maar vooral voor je kritische blik om een abstract of een artikel zo aan te passen dat de boodschap duidelijker werd. Verder wil ik mijn copromotor Dr. A.H. Maass bedanken. Beste Alexander, sinds jij naar het UMCG bent gekomen heeft het onderzoek naar de cardiale resynchronizatie een vogelvlucht genomen. De ideeen om het onderzoek en de behandeling van de individuele patient te verbeteren hebben in belangrijke mate bijgedragen aan de totstandkoming van dit proefschrift. Graag wil ik Maarten P. van den Berg bedanken voor het in mij gestelde vertrouwen en de mogelijkheid om de opleiding tot cardioloog te volgen. De leden van de beoordelingscommissie, prof. Dr. J.J. Bax, prof. Dr. J.L.R.M. Smeets en prof. Dr. WH. van Gilst wil ik bedanken voor de bereidheid om mijn proefschrift kritisch te beoordelen. De pacemaker kamer, Henk, Hanny, Pieter, Dick, Meint, Ester en Henk wil ik bedanken voor de plezierige samenwerking bij de vele studies (ASSERT, DOT-HF, EFFECT en het CRT protocol), en hierbij natuurlijk in het bijzonder her CRT protocol, zonder jullie inzet zou het nooit zo goed hebben kunnen lopen. Maar ook voor jullie haast onuitputtelijke energie om uit te leggen hoe pacemakers, ICD's en CRT's werken en ingesteld moeten worden. Dir proefschrift zou nooit tot stand zijn gekomen als de patienten niet vrijwillig hadden meegewerkt aan het CRT-protocol in het UMCG. Ik ben me volledig bewust van her feit dat participatie aan het CRT-protocol een grote belasting kon vormen, aangezien alle patienten die her CRT-protocol volledig hebben doorlopen op 6 maanden en na I jaar bijna een gehele dag in het UMCG hebben doorbracht in verband met de te verrichten onderzoeken, te weten een echo cor, een MUGA scan, pacemaker controle en een inspanningsonderzoek (V02 max). Maar daarnaast ook een AV optimalisatie echo op 2 weken en sinds kort een inspanningsonderzoek 2 maanden na implantatie. Bedankt voor de uitstekende cooperatie. 
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Dankwoord Graag wil ik de cardiologen van de maatschappen Cardiologie van Wilhelmina Ziekenhuis Assen, Delfzicht Ziekenhuis Delfzijl, St. Chr. Zorgvoorzieningen Talma Sionsberg Dokkum, Chr. Ziekenhuis Nij Smellinghe Drachten, Scheperziekenhuis Emmen, Martini Ziekenhuis Groningen, De Tjongerschans Ziekenhuis Heerenveen, Ziekenhuis Bethasda Hogeveen, Medisch Centrum Leeuwarden, Diaconessenhuis Meppel, Antonius Ziekenhuis Sneek, St Chr. Ziekenhuis Refaja Stadskanaal, St Lucas Ziekenhuis Winschoten bedanken. Zij verwezen hun patienten naar her UMCG voor een CRT(-D) implantatie. Zo heb ik dit proefschrift kunnen schrijven. Zonder de sponsoring van de firma's Medtronic, Biotronik, St. Jude en Boston Scientific, zou her nooit mogelijk geweest zijn om dit proefschrift tot zijn voltooiing re brengen. Hun financiele ondersteuning van her CRT onderzoek in her UMCG wordt ten zeerste op prijs gesteld. De dames van de HC betrokken bij de ICD planning, Dianne, Liesje en Ester, heel war ICD vergaderingen heb ik met jullie meegemaakt. Bedankt voor her vroegtijdig doorgeven van de ICD planning en her bijhouden van mogelijke studie kandidaten zodat de verschillende studies niet in her geding kwamen. De holter-kamer, Joke, Jaap, Patricia, Janet, Carien, Hendrina, Tallien, wil ik graag bedanken omdat ze altijd op her laatste moment een halter wilden aan plakken, een halter met spoed wouden beoordelen. De dames van cluster A, Antoinet, Agnes, Didi en Hayad, wil ik bedanken voor de ondersteuning met her regelen van de poli afspraken en de multiple onderzoeken voor de CRT patienten, de prettige samenwerking tijdens de poli en her regelen dat de juiste patienten de vragenlijsten ontvingen en her juiste laboratorium onderzoek werd verricht. Natuurlijk wil ik ook de medewerkers van de echo kamer bedanken, aangezien ze altijd bereid waren verschillende echo metingen uit re leggen en een TVI vier kamer opname re maken. Alma en Audrey, secretaresses op de vierde verdieping, wil ik bedanken voor alle hulp. Als er iets geregeld moest warden kon ik jullie altijd bellen. De verpleging op C l  VA wil ik bedanken voor de hulp bij de vele cardioversies. Bauk, secretaresse van de CCU, wil ik bedanken voor de leuke samenwerking en hulp bij her plannen van patienten in de cardioversie-agenda. Natuurlijk wil ik ook mijn collega-onderzoekers bedanken. In willekeurige volgorde: Sheba, Jan Pieter, Hessel, Marcelle, Walter, Lianne, Martin, Anne, Tone, Pieter, Jessica, Kevin, Daan, Jasper, Suzan, Willem-Peter, Lieuwe, Ali, Liza, Jardie, Marieke, Bart, Michiel, Youlan, Wim, Marte. 
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Dankwoord De afdeling Cardio Research wil ik bedanken voor de inzet bij de vele commerciele studies (Convert, cardiome, Rely, DAPA, ARDA, Rocket AF enz) die we de afgelopen jaren hebben gedaan. Verder wil ik mijn beide paranimfen, Kim Buck en Lianne Permentier bedanken. Beste Kim, recentelijk is mijn neefje geboren, maar toch wou je graag aan mijn zijde staan, je geduld met mijn werkzaamheden stel ik zeer op prijs. Beste Lianne, je hebt je tijdelijk verdiept in cardiale resynchronizatie therapie, terwijl ik als arts assistent op de afdeling bezig was hebben we vaak overleg gehad. Ook wil ik mijn vrienden bedanken. Zonder jullie geduld als het weer eens druk was in Groningen was het niets geworden. Ik wil mijn vader bedanken. Lieve Eduard, de mogelijkheden die jij en Kathleen mij en Kim altijd hebben geboden, in combinatie met jullie eeuwige steun waardeer ik immens. Kate is er vandaag niet bij maar in gedachte is ze zeker aanwezig. Tenslotte, mijn verloofde Patrick, ik heb her ongelofelijk getroffen met jou, en ik wil je dan ook bedanken voor al je liefde, steun en geduld. 
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